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Pulmonary aerosolized delivery of drugs incorporated into nanocarriers 
(nanodrugs) by inhalation is a promising route for the prolonged treatment of 
lung diseases such as pulmonary hypertension or lung rejection after transplan-
tation. Due to the lack of validated in vitro testing systems, the PK and efficacy 
of nanodrugs during the preclinical phase of drug testing has to be measured in 
animal models. 
This work investigates the particokinetics of two nanodrugs, Ptx-NP and L-CsA, 
which incorporate the active drug Paclitaxel (Ptx) and Cyclosporine A (CsA) into 
polymeric or liposomal nanocarriers, respectively. The goal of the study was to 
evaluate the potential of aerosolized drug delivery combined with physiological 
in vitro cell culture models of the lung to predict the clinical outcome with a fo-
cus on PK.  
The VITROCELL® Cloud 6 system was used to deliver the nanodrugs in aero-
solized form to in vitro models of the healthy and diseased human alveolar air-
blood barrier cultured at air-liquid interface (ALI) conditions, and to analyze the 
transbarrier transport of the incorporated drugs. ALI conditions showed a direct 
cell-nanodrug interaction, which allowed clarifying cellular uptake mechanisms 
(caveolae-mediated endocytosis and passive diffusion) and mirroring real cellu-
lar transport rates. In a direct comparison between the healthy and diseased 
models, no significant differences in the transbarrier transport rates were found, 
which highlight the prolonged tissue-association of drugs incorporated in 
nanocarriers. The obtained particokinetics were further combined with physio-
logical-based PK (PBPK) modeling to predict the PK profile of CsA and Ptx (e.g. 
maximum drug concentration cmax in the blood; time until cmax is reached (tmax)) 
after inhalation. This confirmed that cmax levels after inhalation were achieved 
fast (< 0.25 h). Moreover, the modeling revealed that cmax levels after inhalation 
are typically low, which highlights the advantage of targeting lung diseases by 
inhalation therapy as this avoids high drug levels in the blood that could lead to 
systemic toxicities. 
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Besides the PK, the efficacy of Ptx-NP was investigated. The analysis of Ptx 
doses in different compartments of the in vitro model demonstrated a cell-
association of 30% of the initial dose 24 h after the aerosolized delivery of Ptx-
NP. Accordingly, the potential of prolonged drug interaction with the diseased 
tissue in vitro could be highlighted. Moreover, a dose of 0.7 µg Ptx/cm² in-
creased FoxO1 transcription – a hallmark of pulmonary hypertension - by a fac-
tor of 3 as compared to untreated control.  
Consequently, the aerosolized drug delivery to ALI cell culture models of the 
alveolar tissue barrier combined with PBPK modeling can support the develop-
ment of drug formulations with a beneficial PK profile in the clinical settings. 
Moreover, these types of in vitro models are well suited to study cellular uptake 
and transport mechanisms.  
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1 Introduction 
Lung diseases can be therapeutically targeted via systemic delivery of drugs 
(e.g. intravenous drug application) or via inhalation [1]. However, systemic de-
livery of drugs for the treatment of lung diseases demonstrates two significant 
disadvantages. The administration route can lead to a reduced drug dose in the 
lung [2, 3] as the applied drug is subjected to enzymatic degradation in eliminat-
ing organs (such as the liver) or other degradation ways in the blood stream [1]. 
Moreover, systemic delivery increases the risk of the onset of adverse events 
[1, 4]. On the other hand, inhalation therapy targets the lungs directly, which 
implies that the entire delivered drug dose is initially available in the target or-
gan (lung) and only gradually some of it will get transported in secondary or-
gans. This leads to a high therapeutic index, i.e., it provides high efficacy in the 
lung relative to the invested amount of drug and it minimizes the risk of adverse 
(side) effects in secondary organs  [5-7]. 
Inhalation therapies are well established for the treatment of chronic obstructive 
pulmonary disease (COPD), asthma, and pulmonary infections. For instance, 
the antibiotics levofloxacin and tobramycin are widely used for the treatment of 
pulmonary infections in cystic fibrosis patients [8, 9]. For the treatment of asth-
ma and COPD, inhaled corticosteroids are part of the standard therapy [10]. 
Current trends in inhalation therapy include the use of biologics such as pep-
tides and proteins due to the their specific binding to therapeutic molecular tar-
gets in diseased lung tissue and due to the potential of established methods 
such as antibody engineering to increase the stability in the diseased tissue 
[11]. Besides COPD, asthma, and pulmonary infections, treatment of lung can-
cer via inhalation is another important research field [12]. However, some inves-
tigated agents (e.g. chemotherapeutic agents such as Paclitaxel for lung can-
cer) have strong hydrophobic properties, demonstrate poor solubility, and there-
fore poor tissue penetration, which requires optimization of the drug formulation 
to guarantee high drug association in the tissue [13, 14].  
To increase the drug association in the diseased lung tissue after inhalation and 
to enhance the solubility of the drug, the incorporation of drugs into nanocarriers 
(nanodrugs) is a prominent option [15, 16]. One prominent nanodrug example, 
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which will be highlighted in the present work, is the peptide Cyclosporine A in-
corporated into liposomal nanocarriers (L-CsA) [17]. L-CsA is used to treat 
bronchiolitis obliterans (BOS), and is currently in the clinical phase III [18]. In 
addition, the present work has a strong focus on the hydrophobic drug Paclitax-
el incorporated into polymeric nanocarriers (NanoPAX). Paclitaxel has shown 
potential to treat pulmonary arterial hypertension (PAH) in animals [19], and its 
polymeric formulation is currently in the preclinical development. 
After inhalation, the lung retained drug dose is determined by interactions with 
the lung epithelium [20]. Transport processes characterize these interactions, 
leading to partial transport of the inhaled drug from the lung directly into the 
blood (systemic absorption) [21]. Together with distribution and elimination 
mechanisms in the blood, absorption of a drug by the blood circulation after in-
halation is typically referred to as pharmacokinetics (PK) [7], which is an essen-
tial element of the regulatory drug approval [22]. Consequently, lung epithelial 
permeability of drugs is directly linked to pharmacokinetics (blood). Several 
methods aiming to predict the systemic absorption based on epithelial permea-
bility have been introduced over the past years (for a review see Bosquillon et 
al. (2017) [23]). These also include in vitro strategies ensuring “the principles of 
the 3Rs (replacement, refinement, reduction” [24] of animal experiments. 
The motivation of the present work is to assess epithelial permeability with 
physiological cell-based models and an in vitro air-liquid interface cell exposure 
system. Transepithelial transport rates will be assessed and used to describe 
the lung-to-blood transported dose. This will ultimately allow prediction of the 
pharmacokinetics (PK) profile (in the blood) of L-CsA and NanoPAX after inha-
lation in vivo. 
  









Figure 1.1: Graphical summary of the motivation. Nanodrugs will be aerosolized on in vitro cell-
based models. The transbarrier transport will be transferred into PK by matching in vitro data 
with relevant in vivo data. 
The following sections will provide background information on topics related to 
the main objective of the thesis including the use of nanocarriers for drug deliv-
ery to the lung, the role of the lung epithelium in transepithelial transport of aer-
osolized drugs by various cellular transport pathways, and computational ap-
proaches aiming to translate in vitro findings on epithelial permeability into rele-
vant in vivo pharmacokinetics parameters. Since these issues are addressed 
with two types of nanodrugs for the treatment of PAH and BOS, some back-
ground on these diseases will also be presented here. 
 Inhalation of nanodrugs 
Inhalation delivers drugs to the lungs of patients directly, which promises a high 
local dose, fast onset of action, and fewer systemic side effects than oral or in-
travenous administration of drugs [6, 7]. Typically, nebulizers are used to apply 
the drugs in aerosolized from the patients [25]. Treatment of lung diseases by 
inhalation as compared to intravenous application is further promoted by the 
fact that the presence of drug-metabolizing enzymes in the lung is less in com-
parison to other organs such as the liver, which prevents the generation of 
complex metabolites [26]. With regard to patient compliance, inhalation was 
found to be the most preferred administration way out of six routes of acute 
breathlessness patients [27]. 
Barriers in the lung against uncontrolled particle transport into the blood circula-
tion include the lung lining fluid, the lung epithelium, and the endothelium [28]. 
Matching of in vitro 
 
transbarrier transport rates (→) 










Basal medium = „blood“ 
cells = „lung“ 
Aerosolized nanodrugs 
1 Introduction  15 
 
These barriers determine the retention of the applied drug at the target site 
(here the lung) and amongst the most relevant processes are the so-called 
clearance mechanisms, which result in removal of the drug from the lung. The 
main clearance mechanisms are mucociliary clearance, uptake by alveolar 
macrophages, and metabolic degradation by lung-associated enzymes [25, 29, 
30]. An additional clearance mechanism is trans- or paracellular transport of the 
drug through the thin epithelial-endothelial (air-blood) barrier (0.2 µm – 0.4 µm 
[31]), which enables fractional drug transport into the systemic circulation (sys-
temic absorption) [32]. Thus, inhalation typically leads to a least partial transport 
of the inhaled drug from the lung directly into the blood [21], which is referred to 
as PK [7]. PK studies are an essential part of clinical drug testing, since they 
provide insights into the bioavailable dose and – in the context of lung diseases 
– it is a measure of inadvertent exposure of secondary organs potentially lead-
ing to side effects [33-35]. 
   
Figure 1.2: Typical PK parameters are the maximum concentration in the serum (cmax), the time 
until cmax is reached (tmax), and the half life time (t1/2). 
Although drugs can be cleared in different ways, the goal of inhalation therapy 
for lung diseases is to achieve a high concentration in the lung [7]. To increase 
the residence time of an inhaled drug in the lung, various drug delivery carriers 
were developed in the last years [36]. Interestingly, a drug can be modified by 
different physicochemical methods to act as a drug reservoir with sustained-
release properties itself [36]. One example includes Paclitaxel (Ptx)-crystals, 
which were developed to treat non-small cell lung cancer [13, 37]. However, 





























1 Introduction  16 
 
which are designed to provide specific and efficient drug release [38]. Promi-
nent examples for nanocarriers in inhalation therapy include polymeric and lipo-
somal nanocarriers [39], which allow the “particle-based” application of drugs 
[40].  
One commonly used compound for polymeric nanocarriers is Poly(lactic-co-
glycolic acid) (PLGA) due to its non-toxic, biocompatible, and biodegradable 
properties [39, 41]. Polymeric nanocarriers show significant advantages such as 
adjusted drug release rate, enhanced penetration into lung lining fluid, and the 
possibility of specific cell targeting [42]. One example is Budesonide incorpo-
rated into PLGA-nanocarriers, which displays enhanced tissue penetration and 
thus enhanced efficacy [43]. Another example for successful drug loading into 
PLGA-nanocarriers is Rifampicin [44].  
In addition to polymeric nanocarriers, liposomal drug formulations for inhalation 
therapy have already been in focus since the 1990s [45-48]. Liposomes are lipid 
vesicles consisting of a lipid bilayer (for hydrophobic drugs) and an aqueous 
core suitable for hydrophilic drugs [39]. Liposomal formulations exhibit signifi-
cant advantages in comparison to conventional formulations. For example, to-
bramycin in a liposomal formulation applied to rats demonstrated enhanced effi-
cacy in the treatment of a bacterial infection [49] and liposomal beclomethasone 
showed superior lung retention in asthma patients [50]. Increased lung retention 
was also found for liposomal amikacin, which was detectable even 50 hours 
after administration in healthy volunteers [51]. 
In conclusion, current strategies in inhalation therapy often focus on the design 
of nanocarrier systems to enhance the tissue penetration of drugs and to avoid 
fast clearance of drugs by various mechanisms, which have a strong impact on 
the PK profile of a drug. 
 Physiological-based pharmacokinetic (PBPK) modeling 
To predict the PK of drugs already in the preclinical phase, physiologically 
based pharmacokinetic (PBPK) models can be applied. They are computational 
models describing the distribution of drugs over time throughout the entire or-
ganism [52, 53]. Moreover, these models consider different parts/organs of the 
body and drug exchange amongst them via the blood circulation and possibly 
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other drainage systems such as the lymphatic network [53]. Chemical proper-
ties of the drug (e.g. molecular weight and solubility) and biological parameters 
(e.g. enzymatic degradation or transbarrier transport rate) are linked by mathe-
matical approaches (transport equations) to describe the contribution of differ-
ent organs to the fate of the drug after administration [54, 55]. These equations 
include drug-organ-specific rate constants, which often have to be determined 
empirically from either in vitro or in vivo (animal) models or from previously ob-
tained clinical data [56]. In fact, the term “physiologically-based” implied the 
need for access to these kinds of data. One important output of these models is 
the PK profile of the drug (in the blood) after drug administration [54], which is 
one of the key parameters required for regulatory approval of a new drug [57].  
A simplified PBPK model structure with transport rates indicated by arrows 








Figure 1.3: Simplified structure of a PBPK model. A PBPK model describes drug exchange 
amongst different organs/parts of the body by transport rates (indicated by arrows).  
Several PBPK models focusing on the fate of drugs after inhalation were de-
scribed in the past years. A model highlighting the relevance of the application 
route (inhalation vs. intravenous administration) was successfully implemented 
by Fridén et al. (2018), promising to allow selection of appropriate doses for the 
onset of action [58]. A model to analyze the influence of lung surface liquids 
(e.g. mucus) on the PK of a liposomal nanocarrier (liposomal Ciprofloxacin) af-
ter inhalation was published by Finlay et al. (2018) [59]. Campbell et al. 
(2015)[60] reported a model of butadiene, which included metabolic degradation 
of the drug in the lung. It was found that the experimentally determined systemic 
concentration after butadiene inhalation in rats, mice, and humans was compa-









Rest of the body 
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and Hochhaus (2013) presented a PBPK model that included mucociliary clear-
ance and drug deposition in different compartments of the lung [56]. 
Due to the complex lung structure and the various drug clearance processes, 
PBPK modeling in inhalation therapy still requires further optimization [61].  
As PBPK models require access to physiological relevant characteristic param-
eters (mainly rate constants) from “different sources of literature data, in vitro 
data, or educated guesses” [56], one option to improve the output of PBPK 
models is to optimize the predictive power of in vitro models. 
 Epithelial permeability studies 
One of the key parameters of reliable PBPK models for inhaled drugs is the rate 
of transport of the drug/nanocarrier across the epithelial-endothelial tissue bar-
rier from the lung into the blood, often referred to as permeability [23]. This is an 
important parameter as the epithelial-endothelial (air-blood) barrier influences 
the clearance of lung deposited drugs [26, 32]. 
Epithelial permeability can be investigated by in vitro cell models on commer-
cially available Transwell® inserts. However, there is a large variety of potential-
ly suitable cell-based in vitro models both in terms of cell type and culture condi-
tions. Both aspects were considered for selection of the most suitable in vitro 
cell model for the nanocarrier-based drugs investigated in the present study. 
With regard to culture conditions, epithelial permeability studies can be run un-
der air-liquid interface (ALI) or submerged conditions (figure 1.1). At ALI condi-
tions, the cells are supplied with growth medium only from the basal side, 
whereas submerged cell culture supplies the cells completely with growth medi-
um [62]. As the human lung presents an interface between air and blood [31], 
ALI cultures are a more physiological way to simulate the lung in vitro [63]. 
  








Figure 1.4: Comparison of cell culture conditions on Transwell® inserts. While cells are com-
pletely covered with medium at submerged conditions, Air-liquid interface culture (ALI) supplies 
the cells only from below (basal compartment). ALI cultures provide a more physiologic model 
for inhalation therapy and drug transport into the blood (basal compartment). 
Another key issue for any cell-based in vitro model is the selection of the most 
suitable cell type, which will depend on the particular scientific question to be 
addressed. For pulmonary drug absorption into the blood, a model for the alveo-
lar air-blood barrier appears to be most suitable but frequently bronchial epithe-
lial cells have been used for absorption/permeability studies mainly due to limi-
tations with currently available alveolar barrier models [64]. Nevertheless, each 
of these cell culture models has advantages and limitations mainly related to the 
simulation of all involved physiological conditions (e.g. shear stress, flow condi-
tions, and involvement of immune cells) [65]. An overview of frequently used 
cell types with a discussion of their advantages and limitations is provided by 
Bur and Lehr (2008) [66]. The most frequently used cell types for transport stud-
ies include bronchial (Calu-3, 16HBE14o-) [67, 68], and alveolar epithelial cell 
lines (A549, NCI-H441, hAELVi) [68-70]. 
For many drugs, there is a good correlation between in vitro epithelial permea-
bility and in vivo drug absorption into the blood. ALI cultured Calu-3 cells were 
used to study the transport of dextran molecules of various sizes by Grainger et 
al. (2009)[71]. It was shown that the mass transported through the in vitro barrier 
correlated linearly with the clearance of dextran molecules (e.g. by absorption) 
of the same molecular weights (sizes) from a canine lung [71, 72]. Similarly, 
Mathia et al. (2002) found a linear correlation of the transport profiles for various 
molecules (e.g. Lucifer yellow or mannitol) obtained from ALI cell models and a 
rat lung [67]. 
Submerged  Air-liquid interface (ALI) 
basal 
apical 
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In spite of the good correlation between in vitro and in vivo permeability, there 
are fundamental differences between transport rates observed for submerged 
and ALI cell cultured models. For instance, Trammer et al. (2008)[73] have 
shown that a liposomal formulation of Cyclosporine A (L-CsA), which is used to 
treat lung rejection after lung transplantation [17], exhibited a weaker permeabil-
ity across a Calu-3 cell monolayer than a propylene glycol formulation of this 
drug. In this study, the Calu-3 cells were cultured at submerged conditions, and 
thus the cells were covered with growth medium in the basal and apical com-
partment of a Transwell® insert, respectively. The drug formulations were pipet-
ted into the apical compartment of the Transwell® insert and linear transport into 
the basal compartment was measured [73]. In contrast to this, Schmid et al. 
(2017)[68] used an A549 cell monolayer, which was exposed to L-CsA in aeroso-
lized form. It was shown that L-CsA was transported with an initial burst into the 
basal compartment [68].  
Meindl et al. (2015)[74] reported a direct comparison of permeability between 
submerged and ALI conditions. Various molecules (e.g. fluorescein, 
budesonide) were delivered to the cells and the epithelial permeability was in-
vestigated. It was found that the ALI culture demonstrated faster transport rates 
[74], suggesting that ALI culture facilitates the permeability of the used com-
pounds. In conclusion, ALI transport rates are typically higher and have a burst-
like temporal profile.  
The concept of combining in vitro cellular transport rates with PBPK modeling of 
pulmonary applied nanoparticles was presented by Bachler et al. (2015)[52]. 
Gold nanoparticles of different sizes were nebulized onto ALI cultured A549 
cells (alveolar epithelial cells) and transport rates were derived from the tem-
poral dose of nanoparticles in the basal compartment. Moreover, transport rates 
of these nanoparticles were combined with PBPK modeling to predict organ 
doses for the same set of gold nanoparticles intratracheally instilled to mice 
[52]. 
There are numerous cell-based in vitro permeability assays, which have predic-
tive capacity for in vivo transport rates of inhaled drugs/nanocarriers. Historical-
ly, most of the in vitro data has been obtained with cells at submerged condi-
tions, albeit ALI cells are more physiologic. Quantitative comparison between in 
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vitro and in vivo transport rates are rare and typically require complex computa-
tional PK modeling. 
 Enhancing the in vivo relevance of in vitro models 
The prediction of relevant in vivo parameters is typically referred to as in vitro-in 
vivo-correlation (IVIVC) [67, 75]. Although different IVIVC strategies were de-
veloped, physiologically more relevant models are required to optimize the pre-
dictive power of in vitro results [76, 77].  
One strategy to improve the predictive power of in vitro models includes the ad-
dition of further cell lines or the use of primary cells. For instance, the simple 
A549 cell model on commercially available Transwell® inserts was further ex-
tended by adding endothelial cells, mast cells, and macrophage-like cells [78]. 
This tetra-culture model was used to analyze the effect of nanometer and mi-
crometer-sized silver particles on cell viability, cytotoxicity, generation of reac-
tive oxygen species, and pro-inflammatory response [79]. Furthermore, dendrit-
ic cells and alveolar macrophages were added to the A549 cell model on 
Transwell® inserts to analyze the interplay of particle uptake by the cells [80, 
81]. Also, primary cell models of the alveolar epithelium have recently been pre-
sented [82]. 
However, even the most complex multi-cell mode of the alveolar barrier has 
limitations. One major drawback of the human lung cell culture on commercially 
available Transwell® inserts is that their thickness (ca. 10 µm) is much larger 
than that of the basement membrane of the pulmonary air-blood barrier (< 
1 µm) [83]. Therefore, alternative membranes and scaffolds for the growth of 
lung cell lines have been developed [83, 84], mirroring another strategy to in-
crease the in vivo value of in vitro models. Unlike Transwell® inserts, scaffolds 
have the advantage of getting modified by different physiological parameters 
[85]. For example, the addition of shear stress was shown to influence cellular 
transport of molecules significantly [86]. Another strategy to improve the biomi-
metic characteristics of cell-line based in vitro models of the alveolar barrier is 
the addition of surfactant or even lung lining fluid [79]. 
Finally, improving the experimental setup can increase the predictive power of 
in vitro models. Aerosolized drug delivery is one example for more physiologi-
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cally simulating the clinical conditions during inhalation therapy under in vitro 
laboratory conditions. Most currently available in vitro technologies for aerosol-
cell delivery are limited in terms of delivery rate, i.e. exposure times exceed the 
clinically acceptable range of up to a few minutes per application [87]. One of 
the few exceptions the Air Liquid Interface Cell Exposure (ALICE) technology 
for liquid drugs, which was first published by Lenz et al. (2009) to deliver nano-
particles and molecules to cells grown on Transwell® inserts [88], and then re-
fined into the ALICE Cloud system for dose-controlled, aerosolized drug deliv-
ery to ALI cell culture models of the lung [89]. Meanwhile, the latter system was 
commercialized as VITROCELL® Cloud 6. 
 Advantages of air-liquid interface cell exposure 
As mentioned, human lung cell culture is either carried out at submerged or at 
ALI conditions. Over submerged conditions, ALI culture demonstrates several 
different outcomes.  
First of all, ALI culture demonstrates different transbarrier transport rates in 
comparison to submerged cell culture.  In detail, a burst-like transport profile 
can be observed when molecules and nanodrugs are delivered to cells at ALI 
conditions [68, 74].  
Another difference concerns the response to environmental nanoparticle expo-
sure. Ghio et al. (2013)[90] have shown that ALI cultured human bronchial epi-
thelial cells demonstrated a reduced inflammatory response to air pollution par-
ticles in comparison to submerged cultured cells. They found that the hypoxic 
conditions at submerged conditions together with the particles led to inflamma-
tion. Thus, ALI culture demonstrates increased availability of oxygen, preventing 
the hypoxic conditions that could occur at submerged conditions [90]. De-
creased inflammatory response to allergen coated nanoparticles was also 
shown for hAELVi cells at ALI conditions compared to submerged conditions 
[91]. 
ALI culture further displays faster onset of drugs. In a direct comparison be-
tween both cell culture modes by Lenz et al. (2009), the ALI culture led to faster 
uptake of the proteasome inhibitor Bortezomib [89]. As mentioned by Röhm et 
al. (2019), this can be led back to the fact that ALI exposure decreases the de-
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gree of protein aggregation, which happens at submerged conditions [92]. An-
other advantage of ALI culture and exposure relates to the dosimetry. Contrary 
to submerged cell models, ALI exposure guarantees a direct measure of the 
cell-delivered dose [63]. This advantage can be used to directly measure the 
onset of effects after nanoparticle exposure [88, 93]. 
Finally, ALI culture was shown to resemble essential in vivo characteristics. ALI 
culture of  human induced pluripotent stem cells was shown to promote the dif-
ferentiation into an alveolar epithelium phenotype [94], and to resemble the 
transcriptome of the airway epithelium [95]. 
All in all, ALI culture of lung cells has significant effects on the transbarrier 
transport of drugs/nanodrugs/nanoparticles, inflammatory responses, differenti-
ation, and on the estimation of the onset dose in toxicological studies. However, 
the clinical relevance of these differences still has to be validated. 
 Transport mechanisms for nanodrugs 
Epithelial permeability for drugs or nanodrugs depends on the barrier function of 
the human lung and the transport of these compounds across the barrier [20]. 
The barrier function is characterized by tight junction proteins [96, 97]. They are 
assembled by the transmembrane proteins Occludin, Claudin, and Junctional 
adhesion molecules (JAMs) that are linked to the Actin cytoskeleton via the cy-
toplasmic proteins ZO-1, ZO-2, and ZO-3 [98].  
Transport across biological barriers can be distinguished between paracellular 
and transcellular transport [20]. Tight junctions control the paracellular transport 
of the lung epithelium [99], which is the transport of molecules or particles be-
tween the cells [20, 100]. The other way is transcellular transport, which re-
quires cellular uptake of particles or molecules [20]. Endocytosis is one promi-
nent transcellular transport pathway that can be distinguished into four classes: 
caveolae-mediated endocytosis, clathrin-mediated (receptor-mediated) endocy-
tosis, macro-pinocytosis, and phagocytosis [101, 102]. Differences in the endo-
cytosis classes concern the entry mechanism of nanoparticles or nanodrugs 
[103], which lead to the presence of different intracellular protein complexes 
with the nanoparticles or nanodrugs [104]. Although there are different mecha-
nisms of entry, similarities can be found in the fate after the uptake. For 
1 Introduction  24 
 
nanodrugs, a protein-nanodrug complex originates, which fuses with the lyso-
some after cellular uptake and several intermediate steps, finally leading to the 
release of the drug inside the cell [105, 106]. 
The hydrophilicity plays a crucial role in the determination of paracellular or 
transcellular uptake. Small hydrophilic molecules or ions can pass an epithelium 
via the paracellular route, while lipophilic molecules rather demonstrate cell-
uptake, possibly due to interactions with the lipid bilayer [26, 107]. Another 
point, which determines para- or transcellular uptake, is the size [26]. This pa-
rameter has extensively been studied for environmental nanoparticles, such as 
polystyrene nanoparticles [100, 108] or latex nanoparticles [109]. Here, it can be 
concluded that nanoparticles > 100 nm prefer transcellular uptake pathways, 
while smaller nanoparticles bypass the cells (paracellular transport) [110].  
The role of size and charge in the transport mechanisms can also be trans-
ferred to nanodrugs. The size of drug loaded nanocarriers (nanodrugs) typically 
ranges from 50 nm – 1000 nm [15]. Thus, transcellular uptake can be expected, 
which was reported by several groups: Stolnik et al. (2018) have shown that 
caveolae mediated endocytosis and clathrin mediated endocytosis were in-
volved in the uptake of 80 – 100 nm-sized cationic liposomes by A549 cells 
[111]. The involvement of clathrin mediated endocytosis was also confirmed in 
the A549 cellular uptake of 155.2 nm-sized cationic liposomes by Huang et al. 
(2018) [112]. Wu et al. (2015)[113] investigated the role of the charge on cellular 
uptake of liposomes by A549 cells. Starting with anionic 100 nm-sized lipo-
somes, they modified the liposomes with peptides, which resulted in a positive 
surface charge. This significantly increased the cellular uptake [113].  
As epithelial permeability not only depends on the transport of nanodrugs but 
also on the barrier function [20], changes in this function is investigated exten-
sively in the context of lung diseases.  Tight junctions are dynamic structures, 
meaning that they can be subject to environmental changes [114, 115]. For in-
stance, these changes include inflammatory conditions in the lung, which were 
found to alter tight junction expression [116-118]. In detail, epithelial tight junc-
tions were affected, leading to higher permeability [116-119]. 
In conclusion, epithelial permeability is a crucial parameter as it determines the 
dose of inhaled nanodrugs in the lung and can be subject to lung diseases.  
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 Molecular and cellular mechanisms of pulmonary arterial 
hypertension (PAH) 
Pulmonary arterial hypertension (PAH) is characterized by enhanced pulmonary 
arterial pressure due to the remodeling of blood vessels [120, 121]. Besides 
smooth muscle cells, endothelial cells are involved in the remodeling via in-
creased proliferation and resistance to apoptosis [122]. In addition, endothelial-
to-mesenchymal transition (EMT) leads to further remodeling of the vascular 
system in the lung via an increase of the smooth muscle cell phenotype [123].  
FoxO1 signaling, which is involved in the regulation of cellular proliferation, is a 
promising target of PAH since the transcriptional activity of FoxO1 was found to 
be downregulated in smooth muscle cells isolated from PAH patients [19]. The 
phosphorylation of FoxO1 leads to the deactivation of its transcriptional activity 
by exclusion from the nucleus [124]. Besides its role in the regulation of prolifer-
ation, FoxO1 is a repressor of the Claudin-5 gene, which regulates the assem-
bly of tight junction proteins [124, 125]. It was found that phosphorylated FoxO1 
increased the amount of Claudin-5 transcripts in acute lung injury, which can be 
interpreted as a rescue mechanism to recover barrier integrity [126]. 
Inflammation is one of the various factors that are involved in the development 
of PAH [127]. Increased TNF-α levels were found in the serum of PAH patients, 
and TNF-α was shown to promote vascular remodeling, leading to impaired bar-
rier properties of the lung endothelium [128-130]. Besides TNF-α, activated 
Signal Transducer and Activator of Transcription 3 (STAT3) was evaluated as 
another key driver involved in the development of endothelial dysfunction [131]. 
Activated STAT3 was further shown to increase the survival and proliferation of 
smooth muscle cells and to increase immune responses [131, 132]. 
As mentioned above, the endothelial barrier is directly affected in PAH [130, 
133]. A healthy endothelial barrier modulates vascularity and acts anti-
inflammatory due to the barrier properties guaranteed by tight junction proteins 
[134]. In the endothelium, these proteins are Occludin and Claudin, which are 
further associated with proteins of the ZO-family [135]. In endothelial dysfunc-
tion as a key element of PAH [122], tight junctions are subject to mitigation 
[136]. This is directly promoted by inflammatory cytokines such as TNF-α and 
IL-6 [137-139].  
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In summary, PAH is characterized by changes in the endothelial barrier integrity 
of the lung. Transcriptional changes activated by inflammatory cytokines are 
among the mechanisms that contribute to the altered barrier properties.  
 Paclitaxel for the treatment of PAH 
Paclitaxel (Ptx) is a drug with cytotoxic and anti-cancer activities, which were 
discovered in 1965 as a result of a plant screening program initiated by the Na-
tional Cancer Institute (NCI) and US department of agriculture (USDA) [140]. 
In the field of PAH, Ptx was found to restore FoxO1 activity in a rat model of 
PAH by dephosphorylating FoxO1 [19, 141]. Moreover, Ptx promoted pro-
apoptotic and anti-proliferative capacities of hyper-proliferative smooth muscle 
cells [19]. Also, physiological parameters, such as the thickness of pulmonary 
arteries were significantly reduced in a PAH rat model [142].  
Meanwhile, the application of the drug was further refined and combined with 
sustained release approaches, e.g. liposomal Ptx [143]. Ptx incorporated into 
100 – 200 nm-sized lipid nanocarriers showed a significant increase in the cyto-
toxicity of murine melanoma cells [144]. Add to this, the levels of pulmonary me-
tastases have been significantly decreased in a murine lung cancer model 
[144]. This reduction was also shown for a murine model of renal cell carcinoma 
[143].  In an in vitro model of lung deposition, the Ptx formulation incorporated 
into the lipid nanocarriers demonstrated a 17-fold increase in the deposition as 
compared to the conventional formulation without nanocarriers [145]. Further-
more, Ptx-crystals (NanoPac®) showed anti-tumor properties in a rodent lung 
cancer model by promoting immune cell infiltration [13, 37]. Prolonged action at 
the target site was also shown for Ptx incorporated into 22 µm-sized PLGA par-
ticles [146].  
In summary, Ptx shows high potential to reverse the transcriptional changes 
that are involved in PAH. 
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 Liposomal Cyclosporine A (L-CsA) for the treatment of 
Bronchiolitis Obliterans Syndrome (BOS) 
A lung disease with epithelial barrier damages and dysfunction is bronchiolitis 
obliterans (BOS) [147, 148]. BOS is linked to lung rejection after lung transplan-
tation [149], and characterized by fibrosis of the lung epithelium [150]. Moreo-
ver, epithelium-mesenchyme transition (EMT) is involved in the development of 
the disease [151]. EMT is linked to a reduction in gene expression of epithelial 
tight junction proteins [152]. This limited expression leads to changes in the bar-
rier function [153], which finally promote the EMT [154]. Disease-related cyto-
kines are IL-8, IL-1β, and TNF-α, which was found to be the key player in the 
initiation of EMT [151]. 
One therapeutic option for BOS treatment is to target immune responses after 
lung transplantation, e.g. by Cyclosporine A (CsA) [155]. CsA is a cyclic peptide 
consisting of eleven amino acids [156], and exhibits its action through inhibition 
of the calcineurin phosphatase activity in T-cells, leading to silencing of immune 
response gene expression [157].  
A clinical study on inhalable CsA was carried out by Corcoran et al. (2014) on 
lung transplantation patients. The study could highlight the effective lung reten-
tion of CsA [158]. To further increase the retention, liposomal nanocarrier for-
mulations of CsA were developed. A liposomal formulation of the drug was al-
ready investigated by Letsou et al. on animals in 1999 [45]. In patients, L-CsA 
was successfully applied via inhalation by Behr et al. (2009)[17]. Most important-
ly, adverse side effects were overall not observed using the nanocarrier formu-
lation of CsA [17]. Toxic effects were also not observed in a L-CsA study from 
2019, and in addition, lung function and survival of lung transplant patients were 
improved [18]. 
All in all, L-CsA demonstrated safety and efficacy in treating BOS. 
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2 Key questions 
This work investigates the potential of currently available non-primary cell-
based in vitro models of the alveolar air-blood barrier to mimic biokinetics and 
efficacy of inhalable nanocarrier-based drugs (nanodrugs) observed under in 
vivo (animal) or clinical conditions. This overall objective was subdivided in the 
following key questions: 
 
• Which challenges do we encounter in the use of simple in vitro models 
on commercially available Transwell® inserts? 
• How are liposomal and polymeric nanocarriers transported into and 
through in vitro lung epithelial cells at ALI conditions? 
• How does a more physiological model of the air-blood barrier, which in-
cludes endothelial cells, affect the transport of nanodrugs? 
• How can in vitro models support clinical development of nanodrugs? 
• How do lung diseases affect the transport of nanodrugs? 
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4 Methods 
Cell-based in vitro models were established on commercially available 
Transwell® inserts and cultured at air-liquid interface conditions (ALI). The VI-
TROCELL® Cloud 6 system was used to deliver inhalable nanocarrier-based 
drugs to the in vitro models. The transport of the drugs across the cellular barri-
er was monitored and combined with physiologically-based pharmacokinetic 
(PBPK) modeling to predict the PK in clinical conditions. Moreover, the fate of 
the nanocarrier-drugs was analyzed by incorporation of fluorescent dyes and 
particle size analysis. 
 Cell culture 
The epithelial A549-Luc(IL-8) reporter cell line, a human lung alveolar epithelial 
type II-like cell line, which was stably transfected with a luciferase reporter gene 
under the control of the of interleukin-8 (IL-8) promoter (IL-8: pro-inflammatory 
cytokine) [159], was cultivated in DMEM/F-12 at 37 °C and 5% CO2. The medi-
um was supplemented with 1% Gentamycin, 1% Penicillin-Streptomycin, and 
10% fetal calf serum. 
The endothelial cell line EA.hy926 was cultivated in DMEM/F-12 supplemented 
with 1% (v/v) Penicillin-Streptomycin and 10% fetal calf serum.  
For the A549-Luc(IL-8)/EA.hy926 coculture, cell seeding density of the endothe-
lium and strategy were adapted as previously described by Klein et al. (2013) 
[78]. Briefly, Transwell® inserts (Costar, 3.0 µm pore size) were turned upside 
down, and the EA.hy926 cell suspension was added. After an adhesion time of 
2 h, inserts were placed back into the culture plate and the A549-Luc(IL-8) cell 
suspension was added, resulting in an epithelial-endothelial model of the air-
blood barrier. Cells were allowed to achieve confluency for 4 days and were 
cultured for 24 h at ALI conditions before the aerosolization of different nanocar-
riers. 
For the in vitro modeling of pulmonary hypertension, EA.hy926 cells were chal-
lenged by TNF-α. In detail, cells were seeded into T75 flasks at a density of 
0.27 ∙ 106 cells/cm². On the third day after cell seeding, the growth medium was 
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replaced with TNF-α-supplemented medium to achieve a dose of 9 ng/cm² and 
18 ng/cm², respectively (see figure 4.1). After 24 h, the A549-Luc(IL-










 Preparation and source of nanodrugs 
Liposomal Cyclosporine A (L-CsA), liposomes with an incorporated FRET pair 
(FRET liposomes), and a polymeric nanocarrier system loaded with Ptx (Ptx-
NP) were delivered to cellular models of the air-blood barrier. 
The FRET pair encapsulated liposomes were developed as described previous-
ly [160]. In brief, 10 mg of soy lecithin and 2 mg of cholesterol were dissolved in 
a 2:1 mixture of chloroform and methanol. The FRET probes (Dil and DiD) solu-
tion in dichloromethane was added to the lipid mixture before the evaporation of 
the solvents under vacuum at 40 °C to form a thin film layer. The liposomes 
were prepared by a thin-film dispersion method, where 2 mL of PBS solution 
(pH 7.4) was added to the lipid film. Thereafter, the resulting mixture was incu-
bated at 40 °C without a vacuum for 30 min. The final concentration of the 
FRET pair in the liposomes was 40 μg/mL. Finally, the liposome size was re-
duced by extrusion with a 100 nm filter membrane. Fluorescence intensity was 
analyzed by an excitation wavelength of 505 nm and an emission wavelength of 
705 nm, respectively. 
Different batches of L-CsA and Ptx-NP were kindly provided by Breath Thera-
peutics GmbH (Munich) and by Alexandra Dalla-Bona and Tobias Gessler from 
the Justus-Liebig University Gießen, respectively. The exact content of the for-










of EA.hy926 cells 
Seeding of the  
coculture 
Aerosol exposure 
Figure 4.1: Timeline of the disease modeling. Only endothelial cells (EA.hy926 cell line) were 
challenged by TNF-α before the establishment of the coculture with epithelial cells (A549-
Luc(IL-8) cells). 
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bilayer of the liposomal carrier, the liposomes are typically between 100 and 
200 nm in diameter and they withstand nebulization with a vibrating mesh nebu-
lizer (as used here) without damaging the liposomes (see Schmid et al. (2017), 
[68]). Lyophilized L-CsA was taken up in 0.25% NaCl to obtain a stock suspen-
sion of 15.1% (w/v).   
Ptx-NP incorporate Paclitaxel into a shell consisting of the polymers polyvinyl 
alcohol and  poly(lactic-co-glycolic acid, the polyester polylactic acid, and to-
cophersolan [161]. The size range of Ptx-NP is within 140 and 200 nm. Lyophi-
lized Ptx-NP were taken up in PBS/dH2O 1:1000 to achieve a stock suspension 
of 4% (w/v). 
Dynamic Light Scattering (DLS) analysis was carried out with a Zetasizer Nano 
ZS90 to obtain the diameter of the nanodrugs before and after nebulization.   
 Air-Liquid Interface Cell Exposure (ALICE) with the 
VITROCELL® Cloud 6 system 
The VITROCELL® Cloud 6 system, first introduced in an early version as Air 
Liquid Interface Cell Exposure (ALICE) technology in 2009 [88], and then re-
fined into the so called ALICE-Cloud technology [89], was used for dose-
controlled delivery of aerosolized nanocarriers to models of the air-blood barrier. 
To aerosolize the nanodrugs, a vibrating mesh nebulizer Aeroneb Pro® was 
used. 
In detail, the wells of the VITROCELL® Cloud 6 were filled with 13 mL PBS. Af-
ter a preheating period of 2 h to 37 °C, Transwell® inserts were placed into the 
wells and the signal of the quartz crystal microbalance (QCM) was set to zero. 
To avoid that the aerosol cloud generated by the VITROCELL® Cloud 6 system 
“escapes” via the lateral openings of the Transwell® insert into the basal medi-
um, so-called media covers (provided by VITROCELL® Systems) were used, 
which close the lateral openings. For biokinetics analysis, 500 µL of the respec-
tive nanodrug formulation (L-CsA: 15.1% (w/v), Ptx-NP: 4% (w/v)) was nebu-
lized on the cells. A sufficient deposition, which is the even distribution of an 
aerosolized drug in the system, was guaranteed using the quartz crystal micro-
balance (QCM), which is integrated in the Cloud system for real-time dosimetry. 
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After the sedimentation period of 5 min, the Transwell® inserts were placed 
back in the 6-well plate to contact the bottom of the Transwell® insert membrane 
and cell culture medium. It is important to mention that t = 0 h in our in vitro bio-
kinetics studies of various nanocarriers corresponds to the end of the aerosol 
delivery period (5 min). Consequently, the transport of nanodrugs before 5 min 
could not be clarified. 
 Transbarrier transport analysis of aerosolized nanodrugs 
Sample processing was adapted from a study of nebulized L-CsA by Schmid et 
al. (2017) [68]. The apical compartment (contact-side of the cells with the air) 
was rinsed three times with 500 µL 0.9% NaCl to wash the nanodrugs from the 
epithelial barrier. The basal compartment (medium below the cells) was trans-
ferred into a cup by pipetting. Finally, the Transwell® insert membrane contain-
ing the cells was cut out and transferred into a cup containing 1.5 mL deionized 
water. To lyse the cells, the cup was frozen in liquid nitrogen and thereafter 
thawed in a 37°C water bath (cell compartment). This was repeated three times. 
The Ptx or CsA concentration in the prepared samples was analyzed by the 
project partners in Gießen and in Munich, respectively, via HPLC-MS/MS. It is 
important to mention that the concentration of the free drug was measured (CsA 
or Ptx, respectively). For L-CsA, the liposomal shell was destroyed with Acetoni-
tril prior to the analysis. 
For biokinetics analysis, a membrane-only control (insert without cells) was in-
cluded to correct for the influence of the membrane on the biokinetics, a math-
ematical approach was applied. The Transwell® insert was separated into three 
compartments that are referred to as cells/apical compartment, membrane 
compartment, and basal compartment (Fig. 4.1). 
  








Figure 4.2: Compartments in the Transwell® insert setup. Dtot describes the cell-deposited aero-
solized drug dose of the respective nanodrug. rc+a describes the fractional amount of Dtot in the 
cells and (apically) attached to the cells. Furthermore, rm describes the fractional drug dose 
attached to the perforated membrane on with the cells are grown. Finally, tb describes the frac-
tional amount of the drug in the basal compartment. 
Dtot describes the cell-delivered dose of the drug after aerosolization of the re-
spective nanodrug formulation. The transported amount of the drug into the ba-
sal compartment is described as tb. For the membrane-only control, the dose, 








When cells are present on the membrane, the membrane itself and the cells 
build a barrier against drug transport into the basal compartment. 
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Inserting (1-1) in (1-2) and setting Dtot as 100% result in equation (1-3): 
 
 rc+a = 1 – tb/tb,0 (1-3) 
 
Dtot:  Cell-delivered dose per Transwell® insert after nebulization 
rm:   Dose retained by the membrane 
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rc+a:  Intracellular and cell-associated dose 
tb:   transmitted dose into the basal compartment when cells are present 
tb,0:  transmitted dose into the basal compartment for a membrane-only 
control 
Thus, the dose of the drug in the cellular/apical compartment, which is referred 
to as cell-associated dose in the presented work, is the amount of the drug 
transmitted by the cell layer, normalized to the transmitted dose of the 
Transwell® insert membrane without any cells.  
It is important to mention that this approach can be used to study the apical and 
cellular retained dose of aerosolized drugs. To calculate the cell-retained drug 
dose only, the following procedure was applied for Ptx-NP: The membrane was 
cut out after three washing steps with 0.9% NaCl from the Transwell® insert. 
Then, the membrane was taken up in 1.5 mL deionized water in a cup. This cup 
was frozen in liquid nitrogen and thereafter thawed in a water bath to achieve 
cell lysis. The procedure was repeated three times.  The measured Ptx dose in 
the cup was then normalized to the cell-delivered Ptx dose (100% = (19.8 ± 1.5) 
µg). In addition, the Ptx storage of a membrane-only control was measured and 
subtracted from the cellular setups. 
 Functional Assays 
The effects of the aerosolized nanodrugs on cellular parameters were assessed 
by several functional assays.  
Metabolic activity (cellular viability) was analyzed by WST-1 assay. After a 
15 min incubation period with the reagent, the conversion into formazan was 
analyzed via absorbance measurement at a wavelength of 490 nm. The ab-
sorbance was normalized to the absorbance of a sham control, which was ex-
posed to the solvent of the used nanodrugs. 
The inflammatory response of the A549-Luc(IL-8) cells was assessed by a lu-
ciferase assay system. Luciferase expression correlates to the activation of the 
IL-8 promoter in these cells [162]. After cell lysis and centrifugation, the lucifer-
ase assay reagent ONE-GloTM was added to the supernatant. Thereafter, the 
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bioluminescence was monitored and normalized to the total protein level. Then, 
the activity was expressed as fold increase compared to the sham control. 
Lactate dehydrogenase (LDH) assay was performed to evaluate possible cyto-
toxic effects after cell exposure. The release of LDH was measured by an ab-
sorbance reader and normalized to the release of LDH by a cell lysate (high 
control = 100% cytotoxicity). 
Barrier quality was assayed by using Blue Dextran 2000 as previously de-
scribed by Horvath et al. (2015) [84]. In brief, the translocation of 0.5 mL 1% 
dextran blue solution in PBS from the apical into the basal compartment was 
measured after 2 h by an absorbance reader (Magellan) at 600 nm and normal-
ized to the transport of the dye across a membrane without cells (= 100% dex-
tran blue translocation). It is important to mention that cells were cultured at 
submerged conditions for the dextran blue assay with 1 mL phenol red free 
growth medium in the basal and 0.5 mL growth medium in the apical compart-
ment, respectively. 
Finally, An Epithelial Volt-Ohmmeter (EVOM) was used to measure the transep-
ithelial electrical resistance (TEER) of the in vitro models of the air-blood barrier. 
The TEER technique is a method to validate the epithelial integrity and tight-
ness [163]. 
For Ptx-NP, also mRNA expression of FoxO1 transcription as a hallmark of 
pulmonary hypertension was investigated in endothelial cells EA.hy926 as de-
scribed in the next section. 
 RNA isolation and qPCR analysis 
As described, an epithelial-endothelial coculture of A549-Luc(IL-8) and 
EA.hy926 cells was used for the Ptx-NP experiments.  
To isolate the RNA of the endothelial cell line (EA.hy926), the Transwell® insert 
membrane was cut out. Then, 300 µL lysis buffer (Buffer RLT®) was added to 
the endothelial side of the membrane. After an incubation period of 10 min in 
the fridge, the endothelial cells were scratched off with a cell scraper. After that, 
the lysate was used to isolate the RNA with the RNeasy® Plus Mini Kit accord-
ing to the manufacturer’s instructions. Finally, RNA concentrations were ana-
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lyzed with a spectrophotometer (NanoDrop 1000®) before qPCR analysis in col-
laboration with project partners analogues to [19]. 
 Study of mechanisms of cellular uptake  
Pathways of cellular uptake of nanodrugs were analyzed by the use of inhibitors 
of caveolae-mediated endocytosis (Filipin), clathrin-mediated endocytosis (Pit-
stop-2) and pinocytosis (Amiloride). Concentration and incubation time (10 min) 
were adapted from a previously reported study [101]. These are summarized in 
table 4.1. 
 
Table 4.1: Concentration of the applied cellular uptake inhibitors, adapted from Engelberg et al. 
(2018)[101] 
 Concentration at submerged 
conditions (µM) 
Mass dose per area 
(µg/cm²)* 
Filipin  1.5 0.4 
Pitstop-2 25 4.2 
Amiloride 1000 81.2 
* considering a medium volume of 60 µL and a cell growth surface area of 0.17 cm² using µ-
Slides VI 0.1 by ibidi GmbH, Martinsried, Germany   
 
However, the reported inhibitor concentrations for submerged cell culture exper-
iments were converted into doses in the present study since dose rather than 
concentration governs the bioactivity of substances at ALI conditions [89]. Con-
fluent A549-Luc(IL-8) cells on Transwell® inserts were incubated with 300 µL 
respective inhibitor directly on the cells for 10 minutes at 37°C. Mass doses as 
listed in table 4.1 were applied. Then, the cells were washed twice with PBS 
and exposed to aerosolized nanodrugs. To analyze possible inhibition, the cells 
were washed after exposure three times with 500 µL 0.9% NaCl at various time 
points. The drug dose was thereafter analyzed in the washout by fluorescence 
analysis. 
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 Microscopy 
To visualize the effects of the aerosolized nanodrugs on the cell morphology, 
the actin cytoskeleton of the cells was stained with boron-dipyrromethene 
(BODIPY) in 1% BSA in PBS for 1. Then, the mounting medium with DAPI was 
used to visualize the cell nuclei. Finally, the slides were visualized with the 40x 
objective on a fluorescence microscope (Olympus BX51). 
The incorporation of FRET liposomes was visualized by the Cy3 filter of the mi-
croscope. 
Live cell imaging was performed with cells on the Transwell® insert after the 
nebulization of the FRET liposomes. The inserts were placed in dishes with 
1.5 mL growth medium suitable for microscopy (NuncTM Glass Base Dish). An 
excitation wavelength of 490 nm and an emission wavelength of 700 nm (long 
pass) were used.  Intensity settings and image analysis were performed with 
ImageJ or VisiView. 
To visualize the pores of the Transwell® inserts, Scanning Electron Microscopy 
(SEM) was performed. The membrane of the inserts was cut with a scalpel and 
fixed in 6% (v/v) glutaraldehyde afterwards. Then, the membranes were dehy-
drated in gradient ethanol solutions followed by hexamethyldisilazane for 
15 min. Next, parts of the membranes were mounted onto aluminum stubs and 
sputter-coated using a Leica EM ACE200 vacuum coater. Finally, the mem-
branes were imaged by a Zeiss Crossbeam 240 electron microscope with an 
acceleration voltage of 2 kV. The SEM microscopy of the prepared samples 
was performed by Ali Doryab (Helmholtz Zentrum München) (figure 5.3). 
 Modeling of nanodrug deposition at submerged conditions 
ALI exposure by the VITROCELL® Cloud 6 technology leads to direct deposition 
of Ptx-NP on cells. For comparison with results from cell culture experiments 
under standard submerged cell culture conditions (Figure 1.4), one has to con-
sider that at submerged conditions, nano- and micro particles are pipetted into 
the cell culture media and initially uniformly dispersed throughout the entire me-
dium volume. Depending on the size, shape and density of the NPs as well as 
the height of the medium column in the well (typically 0.3 – 0.5 cm), it can take 
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between a few minutes to a few days until all of the available NPs are deposited 
onto the cells at the bottom of the well [164]. Thus, the fraction of the particles 
that reach the cells at submerged cell culture conditions was calculated with the 
sedimentation, diffusion and dosimetry model (ISDD) described by Hinderliter et 
al. (2010)[164], which allows the calculation of cell-delivered doses. The input 
parameters to calculate the deposition fraction of Ptx-NP at submerged condi-
tions are summarized in table 4.2. 
 
Table 4.2: Summary of the input parameters for the ISDD model for determination of cell-
delivered Ptx-NP dose at submerged cell culture conditions 
 Value Reference 
Volume-weighted median diam-
eter of Ptx-NP (nm) 
260 - 
Area of the  
Transwell® insert (cm²) 
4.2 Costar® Manual 
Effective material density of 
polymeric nanoparticles (g/cm³) 
1.25  
Vauthier et al.  
(1999) [165] 
Height of the cell culture medi-
um on top of the cells (cm) 
0.48a) - 
a) h = V/A = 2 cm³/4.2 cm² = 0.48 cm  
 
The ISDD modeling according to Hinderliter et al. (2010)[164] was performed by 
Dr. Ali Farnoud (Helmholtz Zentrum München). 
 Matching in vitro and in vivo data with focus on PK 
Inhalation of aerosolized nanodrugs leads to lung deposition and time-
dependent partial transport into the blood [21], which is referred to as PK. Here, 
the term lung-to-blood transport was introduced to describe the drug fraction 
transported from the lung into the blood. The lung-to-blood transport was as-
sessed in vitro by aerosolization of L-CsA on A549-Luc(IL-8) cells (= “lung”) and 
measuring the CsA translocation into the basal medium (= “blood).  
To match the in vitro findings with in vivo human (i.e. clinical) data, serum CsA 
levels after inhalation (published by Kappeler et al. 2020[166]) and the peripheral 
lung deposition of L-CsA (published by Behr et al. 2009[17]) were used. This was 
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done with a relatively simple computational approach, which is henceforth re-
ferred to as “simple discrete modeling”. This modeling approach included three 
compartments (lung, blood, and “loss compartment” (e.g. liver)), which are 








Figure 4.3: A relatively simple physiologically based PK (PBPK) model which relies on cell-
based in vitro transbarrier transport rates to predict in vivo pharmacokinetic data of inhaled 
(nano-)drugs. Panel A: Nanodrugs (L-CsA and Ptx-NP) were nebulized onto an alveolar epithe-
lial cell barrier model (A549 w/o EA.hy926) at the ALI. Then, transbarrier transport of the drugs 
from the apical side into the basal medium was measured to obtain the in vitro transport rate 
kLB. Panel B: Combined with the loss rate of the drug from the blood (kloss), which can either be 
obtained from in silico models or from in vivo data, the PK profile of the drugs in humans can be 
predicted (adapted from Bachler et al. (2015)[52]). 
A similar, but more complex multi-organ approach was presented by Bachler et 
al. (2015) [52], who focused more on the multi-organ distribution of inhaled NPs 
rather than the blood concentration. The governing equations and the numerical 
approach of solving them are described in the Appendix for L-CsA as example.  
A conceptually similar but more advanced PBPK model was implemented in 
collaboration with Dr. Ali Farnoud (Helmholtz Zentrum München) using a Py-
thonTM code to solve the inter-compartmental transport equations (figure 5.11). 
This model was adapted from Weber and Hochhaus (2013)[56]. Besides the 
three compartments, which were used in the simple modeling approach de-
scribed above, a remainder compartment was introduced. This compartment 
described the kinetics of absorption of CsA from and release of CsA to the 
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 Statistical analysis 
Results are presented as mean from biological replicates and error bars typical-
ly represent the SEM from three biological replicates unless stated otherwise. In 
addition, fluorescence (FRET liposomes) and absorbance of products in func-
tional assays (LDH, WST-1, dextran blue) was measured in four technical repli-
cates. For TEER measurements, three positions of the electrodes per condition 
were measured. 
A one-way analysis of variance (ANOVA) was conducted to test the statistical 
significance of endpoint measurements (24 hours). To analyze statistical signifi-
cance from data as a function of time (e.g., in biokinetics studies), a two-way 
ANOVA was used. Statistical significance was indicated by stars: * p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. SigmaPlot was used for obtaining re-
gression parameters in simple discrete PBPK modeling. GraphPad Prism 8.0.0 
was used for statistical analysis and generation of graphs. 
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5 Results 
 Transbarrier transport of Cyclosporine A-laden liposomes (L-
CsA) 
One of the goals of this study was to analyze the transbarrier transport of aero-
solized liposomal Cyclosporine A (L-CsA) across A549-Luc(IL-8) cells cultured 
Transwell® inserts and its translation into the corresponding clinical PK profile of 
L-CsA. The study was carried out in three steps, which are 
1) Validation of the dose-controllable delivery of L-CsA by the VITROCELL® 
Cloud 6 system 
2) Analysis of the CsA transport across an A549-Luc(IL-8) monolayer cul-
tured on Transwell® inserts as a model of the air-blood barrier 
3) Finding possible differences in the CsA transport under conditions lead-
ing to a loss of epithelial integrity 
4) Bridging gaps between the in vitro findings and clinical data by computa-
tional approaches 
5.1.1 Evaluation of dose-controllable delivery of L-CsA 
To allow a dose-controllable delivery of aerosolized liposomal Cyclosporine A 
(L-CsA) to the in vitro model of the air-blood barrier, the deposition of L-CsA 
was assessed by the quartz crystal microbalance (QCM) of the VITROCELL® 
Cloud 6 system.  The QCM was placed in one of the wells and the active quartz 
crystal was located at the exact position of the cells cultured in Transwell® in-
serts. Thus, the dose measured by the QCM is equal to that of the exposed epi-
thelial cells [93]. The stock suspension of L-CsA (15.1% (w/v) in 0.25% (w/v) 
NaCl was diluted in several steps, and the cell-deposited dose for each dilution 
was assessed by the QCM. First, the expected fractional nanodrug deposition 
for nebulization of 200 µL of 15.1% (w/v) L-CsA was calculated from the QCM-
measured mass dose per area (scaled to the total area of the VITROCELL® 
Cloud 6 chamber (146.56 cm²)) and compared to the theoretically possible val-
ue, if 100% of the invested drug would reach the bottom of the Cloud system. 
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This yielded a deposition factor of 0.69 (figure 5.1A), i.e., 69% of the invested 
drug deposited on the bottom of the Cloud chamber, where the cells are locat-
ed. Using this information, the cell-deposited L-CsA dose can be calculated 
from the concentration of the L-CsA suspension. It could be shown that for a 
series of different L-CsA concentrations (between 3.0 and 75.5 mg/mL), the ex-
pected and the L-CsA deposition assessed by the QCM correlated with r > 0.99 
(figure 5.1B). Hence, the cell-deposited L-CsA dose can be targeted by select-
ing the appropriate concentration of the L-CsA suspension. Nevertheless, as 
measure of quality control the QCM always served as additional measure of 
dose monitoring during VITROCELL® Cloud exposure experiments. 
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Y = 0.9895*X + 2.064
 
Figure 5.1: Assessment of L-CsA deposition in the VITROCELL® Cloud 6 System with a quartz 
crystal microbalance (QCM). Panel A: A mean deposition factor of 0.69 was obtained. Accord-
ingly, 69% of the L-CsA dose in the nebulizer was evenly distributed on the bottom of the VI-
TROCELL® Cloud exposure chamber, where the cells are located. Panel B: Linear regression 
analysis of QCM-measured and deposition factor-predicted L-CsA dose for all of the formulation 
ingredients (cell-delivered dose) over the entire dynamic range (1 – 70 µg/cm²). Since the frac-
tional dose of CsA in the formulation is 0.057%, a QCM dose of 70 µg/cm² corresponds to a 
CsA dose of 0.04 µg/cm². Thus, the VITROCELL® Cloud 6 technology was capable of detecting 
the cell-delivered L-CsA dose. Error bars represent the SEM from three independent experi-
ments. 
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5.1.2 Transbarrier L-CsA transport studies 
After the dose-controllable delivery of L-CsA by the VITROCELL® Cloud 6 sys-
tem was ensured, the transbarrier transport of CsA across A549-Luc(IL-8) cells 
cultured at the ALI was investigated next. As mentioned above, the model is 
characterized by three compartments (figure 5.2A): the apical compartment 
(contact side of the cells with the air), the basal compartment (medium below 
the cells), and the cell compartment (cells on Transwell® inserts).  
For the transport studies, 500 µL of a 15.1% (w/v) L-CsA stock solution was 
applied in aerosolized form to the cells with the VITROCELL® Cloud 6 system 
yielding a cell-delivered CsA dose of 2.4 ± 0.3 (SD) µg/cm2. The CsA concen-
tration in each compartment (after dissolution of the liposome with a detergent) 
was assessed for a monitoring period of 24 hours and normalized to the total 
amount of CsA per Transwell® insert.  
The fractional CsA dose in the basal (blood) compartment for the setup with 
cells significantly increased from 3% to 62% (Fig. 5.2B, blue line) over the entire 
monitoring period. Interestingly, a similar maximum fractional CsA dose of 
68.5% in the basal compartment was also found for the membrane-only control 
(black line) during the entire time period (even the earliest time point of 7 min). 
This indicates that the membrane itself retains ca. 32 % of the delivered CsA 
dose independent of the presence of the cells. For the assessment of fractional 
transcellular transport of CsA, this needs to be taken into account, by normaliz-
ing the fractional basal CsA dose to 0.68, the maximal possible value for aero-
sol transport measurements with the type of Transwell® inserts used here. A 
more detailed derivation of this numerical correction was presented in the 
methods section. With this correction, only weak CsA apical and cell-
association (5%,) was found after 24 hours (figure 5.2C, red line). On the other 
hand, 88% of the theoretical expected CsA dose was transported across the 
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Figure 5.2: Biokinetics of liposomal Cyclosporine A (L-CsA) across the compartments of A549-
Luc(IL-8) cells grown on Transwell® inserts. Panel A: Schematic depiction of the different 
Transwell® insert compartments for which the drug dose was determined. Panel B: The fraction 
of CsA in the basal compartment (with cells) was increasing with an initial burst (steep slope, 
blue line) to a maximum value of 62%. The membrane itself (without cells) retained 31.5% of 
the delivered CsA (black line), but the corresponding basal CsA fraction of 68.5% was reached 
immediately after nebulization. Panel C: Same data as in panel B, but corrected for the influ-
ence of the membrane on the maximal possible basal dose. The blue line represents the trans-
location into the basal compartment corrected for the membrane influence. The red line repre-
sents the fractional CsA dose in the apical and cell compartment. There was only slight cell-
association of CsA as 88% of the theoretically possible CsA dose per insert was found in the 
basal medium after 24 h (and even after 4 h). Data are normalized to the total CsA dose per 
Transwell® insert ((10 ± 1) µg) and presented as mean ± SEM (n = 11 independent experi-
ments).  
To understand the reason for the membrane retained CsA dose on the 
Transwell® insert, the membrane was visualized by scanning electron micros-
copy (SEM) (figure 5.3). The SEM analysis revealed a highly non-uniform distri-
bution of the 8 ∙ 105 pores/cm² (Corning Falcon® manual) with 3.0 µm diameter 
resulting in a relatively low porosity of 5.65% of the total Transwell® insert area 
(4.2 cm²). Combined with the relatively non-uniform distribution of the pores, 
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30 µm and more. Aerosol droplets of ca. 5 µm diameter depositing in these re-
gions will not be able to transfer their nanocarriers through the membrane, 
which explains the measured membrane retained dose of 31.5%.  
 
   A             B 
                  
Figure 5.3: Scanning electron microscopy pictures of a membrane-only control (Panel A) and 
an insert membrane with A549-Luc(IL-8) cells (Panel B). Areas, which are not stamped by 
pores, were evident. Accordingly, the storage of an aerosolized drug is also possible in the cell-
free setup. Non-confluency in panel B is visible due to sample preparation. Scale bars are 
10 µm. 
5.1.3 Transbarrier transport of L-CsA across an inflamed model of the air-
blood barrier 
To analyze L-CsA transport across the air-blood barrier model under inflamma-
tory conditions, A549-Luc(IL-8) cells were challenged with different TNF-α dos-
es added from below (basal compartment) 24 h before the exposure to L-CsA.  
The addition of TNF-α significantly influenced the barrier integrity of the model. 
ZO-1 prevalence decreased 1.4-fold for 16.1 ng/cm2 (figure 5.4, quantification in 
figure 5.5), which was correlated with a 4.0-fold increase in epithelial permeabil-
ity for the paracellular transport marker dextran blue (figure 5.6A). The IL-8 ac-
tivity of the cells increased up to 100-fold (relative to unchallenged control) in a 
TNF-α concentration-dependent manner (figure 5.6B), showing pro-
inflammatory activation of the epithelial cells. On the other hand, their metabolic 
activity was not decreased for any of the tested TNF-α doses (figure 5.6C), 
which is a prerequisite for the conduction of reliable biokinetics studies. Hence, 
the L-CsA biokinetics studies with pro-inflammatory stimulated cells were per-
formed with the highest TNF-α dose of 16.1 ng/cm2. 
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As seen in figure 5.7D, even severely pro-inflammatorily stimulated A549 cells 
(100-fold IL-8 induction) did not affect the temporal profile of the cell-associated 
CsA dose (apical plus cell compartment) and hence also not the transbarrier 
transport of L-CsA across the inflamed alveolar epithelial barrier model (figure 
5.7D). Since paracellular transport was 4-fold enhanced under those conditions, 
this indicates that CsA is not transported across the cell barrier via the paracel-
lular route. 
 
                ZO-1 (control)                ZO-1 (16.1 ng/cm² TNF-α)               Negative control (no ZO-1 antibody) 
   
Figure 5.4: Tight junction (ZO-1) staining of A549-Luc(IL-8) cells. Panel A: ZO-1 staining with-
out TNF-α (unchallenged control). Panel B: Reduced ZO-1 expression after addition of 16.1 
ng/cm2 of TNF-α via the basal medium (24 h incubation time) relative to unchallenged control. 
Panel C: Negative (technical) control without the addition of a primary antibody against ZO-1. 
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Figure 5.6: Effects of pro-inflammatory challenge via TNF-α incubation (24 h) on IL-8 expres-
sion (promotor activation), barrier integrity, metabolic activity, and L-CsA biokinetics of A549-
Luc(IL-8) cells. Panel A: Compared to the negative control, there was a statistically significant 
(4-fold) increase in paracellular barrier permeability for the highest TNF-α dose only. Panel B: 
TNF-α induced a dose-dependent up to 100-fold activation of the IL-8 promoter (as compared to 
the negative control), which was statistically significant even for the lowest dose (p < 0.0075). 
Panel C: There was no decrease in metabolic activity (WST-1) up to the highest TNF-α dose of 
16.1ng/cm2. Panel D: L-CsA biokinetics across A549-Luc(IL-8) cells, which were challenged 
with 16.1 ng/cm² TNF-α 24 hours before exposure to L-CsA. Although the paracellular barrier 
integrity for large molecules was reduced by a factor of four (panel A), the CsA dose associated 
with the cells (apical+cellular compartment) was not decreased as compared to unchallenged 
control. Data are normalized to the total CsA dose per Transwell® insert ((11 ± 1) µg) and pre-
sented as mean ± SEM (n = 3 independent experiments). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001 
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5.1.4 Matching in vitro CsA transbarrier transport rates with the clinical 
CsA PK profile after inhalation 
The in vitro results presented in the previous paragraphs will now be put into 
context with clinical L-CsA PK data. 
Clinical pharmacokinetic data of L-CsA (time course of CsA serum levels) were 
published by Breath Therapeutics GmbH[166]. In this study, double-lung trans-
plant patients inhaled 10 mg L-CsA as 0.4% (w/v) L-CsA suspension, which is 
identical to the one used for in vitro testing in the present work, and CsA plasma 
levels were monitored from 15 min to 24 h after inhalation (figure 5.7). The PK 
profile showed a concentration maximum of 57.42 ng/mL in the blood, but the 
monitoring time did not start early enough to reveal the peak concentration 
(cmax) and the associated time (Tmax) until peak concentration is reached, which 
are key parameters of PK profiles [166].  
 
































Figure 5.7: Pharmacokinetic profile of inhaled L-CsA in double-lung transplant patients. The 
maximum CsA plasma concentration of 57.42 ng/mL is reached at the earliest sampling time 
(15 min). The plasma concentration of 0 ng/mL at 0 min equals the plasma level 15 min prior to 
the start of the inhalation. These data were obtained by Breath Therapeutics GmbH and pub-
lished in [166]. Error bars represent the mean ± SD of CsA plasma concentrations of n = 7 pa-
tients. 
For translation of the in vitro into the in vivo (clinical) data, various modeling ap-
proaches were used. For the first simple discrete modeling, three compartments 
were introduced according to Figure 5.10: 
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1) Lung compartment, in which L-CsA deposits after inhalation (here: in 
vitro and in vivo parameters were used) 
2) Blood compartment, which describes the lung-to-blood transported 
amount of CsA, leading to a dose in the blood (PK) (predicted from in 
vitro parameters and compared to in vivo results). 
3) Loss (removal) compartment, which describes the depletion of CsA in the 
blood as a result of metabolic CsA degradation and/or excretion (here, in 
vivo parameters were applied). 
 
For connection of in vitro input parameters with the clinically observed CsA 
blood concentrations the following steps were performed:  
First, the lung deposited L-CsA dose in lung transplant patients was obtained 
from the L-CsA inhalation study by Behr et al. (2009) [17], which was conducted 
with the same type of L-CsA (from Breath Therapeutics, formerly Pari Pharma, 
Germany) and a similar type of nebulizer (eFlow, vibrating mesh nebulizer, Pari 
Pharma) as was employed in our in vitro study. Behr et al. (2009) reported a 
peripheral L-CsA lung deposition of 22% of the nominal dose (here: 2.2 mg) 
from radiometric measurements [17]. 
Second, L-CsA transport rates across the air-blood barrier of the lung were de-
rived from the in vitro data reported in chapter 5.1.2. The time-dependent 
transport rates kLB across the A549-Luc(IL-8) cell (lung) barrier corresponds to 
the slope of the basal CsA profile reported figure 5.2C. In this simple discrete 
modeling, the kLB was calculated for each time layer by dividing the fractional 
change in basal CsA dose of adjacent measurement points by the correspond-
ing time interval. It is evident from figure 5.8 that the resulting transport rates 
were about constant at 1.42/h during the first two hours of the in vitro experi-
ment. At 4 h, the transport rate dropped by a factor of 3.5, reaching zero within 
experimental uncertainties for 8 h and later. This rapid drop in kLB is likely due to 
exhaustion of the CsA dose available in the donor compartments (apical, cell). 
These lung-blood transport rates kLB represent the fractional CsA dose per time 
(relative to the time-dependent CsA dose in the associated with the epithelial 
cells/lung), which is transported from the cells (lung) into the medium (blood) for 
in vitro (in vivo) conditions.  
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kLB = (1.42 ± 0.06) 1/h (mean ± 2 SEM)
 
Figure 5.8: The calculated L-CsA in vitro transport rates kLB from the lung into the blood were 
constant (1.42 1/h) during the first 2 h of the in vitro experiment (figure 5.2C). At 4 h, the 
transport rate dropped by a factor of 3.5 and reached zero (within experimental uncertainties) at 
8 h.  
Third, a mean fractional loss rate kloss of 0.51/h of CsA from the blood was cal-
culated analogously to step 2 using the later time points of the L-CsA profile of 
our clinical PK data and taking the average value over all time points (figure 
5.9). 






























kloss = (0.51 ± 0.13) 1/h (mean ± 2 SEM)
 
Figure 5.9: The relative loss rate of 0.51/h serum CsA was calculated from the later time points 
of our clinical PK data (0.51/h) (Figure 5.7).  
Starting from the initial conditions of 2.2 mg L-CsA in the lung (all other com-
partment contain initially zero L-CsA) and an assumed human blood volume of 
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5.75 L [167], the equations listed in Appendix A.1 were applied for each time 
layer of the clinical PK data (figure 5.7), and the resulting CsA PK data (figure 
5.10B, blue line) were plotted together with the clinical data (figure 5.10B, grey 
line). It is evident that the modeled and the measured values agree within esti-
mated experimental and modeling uncertainties of factor of 2 for the first two 
hours. However, they deviate for later times since the modeled curve decays 
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Figure 5.10: Simple discrete modeling of the PK of inhaled L-CsA and comparison to clinical 
data for lung transplant patients. Panel A: Scheme of simple discrete modeling approach and 
the in vitro and in vivo derived transport rates of CsA from the lung into the blood (kLB) and out 
of the blood (kloss). Panel B: Comparison of modeled (grey) and measured (blue) PK curves, 
which showed agreement within estimated experimental uncertainties (ca. factor of 2) at least 
within the first two hours, which are most important for calculating the systemically available L-
CsA dose (clinical data from Figure 5.7). Error bars for the modeled data were calculated apply-








Inhalation of L-CsA  kLB(t) 
k






 (2.2 mg) 
5 Results  57 
 
One of the main over-simplifications made in the simple discrete modeling ap-
proach is that the initial sequestering of some of the L-CsA in the blood in the 
entire rest of the body (remainder) and its subsequent gradual (partial) release 
from there into the blood is not included in the model. In the advanced modeling 
approach, this compartment (remainder) was included (figure 5.11A) and the 
resulting transport equations (Appendix A.2) were numerically solved with a Py-
thon program written by Dr. Ali Farnoud (member of research group of Dr. Ot-
mar Schmid, Helmholtz Zentrum München). The transport rates from the blood 
into the remainder (kBR) and vice versa (kRB) were obtained by minimizing the 
difference between modeled and measured L-CsA concentrations in the blood 
(figure 5.11B). It is evident that there is excellent agreement between modeled 
and measured L-CsA PK profile for the first two hours (model 1 and model 2) 
and even over the entire modeling period of 8 h if the remainder compartment is 
included (model 2). 
  












Figure 5.11: Advanced PBPK models for inhaled L-CsA and comparison to clinical data for lung 
transplant patients. Panel A: Scheme of advanced PBPK modeling approaches using (infinitely) 
small time steps (continuous modeling) and up to four compartments, namely lung, blood, loss 
(removal), and remainder (rest of body) compartment (model 2). For model 1, the remainder 
compartment was not considered (analogous to simple discrete modeling). The lung, blood, and 
loss transport rates were adopted from the simple discrete modeling (see figure 5.10) and the 
transport rates in and out of the remainder (rest of body) were obtained by numerical minimiza-
tion of the difference between modeled and measured L-CsA blood concentrations. Panel B: 
Comparison of modeled (dotted lines) and measured (red symbols) PK curves shows excellent 
agreement over the entire modeling period (up to 8 h) for model 2 (with remainder), but much 
less good agreement for time points later than 2 hours, if the remainder is not included (model 
1) (clinical data from Figure 5.7). 
This demonstrates that in vitro transport rates obtained with the VITROCELL® 
Cloud 6 technology can serve as useful (physiologically-based) input parameter 






































LB = 1.42/h 





BR = 2.48/h 
k




5 Results  59 
 
 Prediction of clinical maximum drug plasma concentration in 
inhalation therapy  
Currently, in vitro transbarrier transport data are limited to a very small number 
of drugs and t for submerged cell culture models, which results in a slower in 
vitro kinetics profile as reported for ALI conditions [74]. Hence, it is unclear if 
these data can be used for the prediction of the clinical outcome at all.  
In an effort to shed light on the effect of different types of inhaled drugs 
(with/without carrier systems) and of the role of drug carriers on PK curves, pub-
lished clinical PK profiles, which reported the maximum (peak) drug concentra-
tion in the blood cmax, were investigated in this thesis (table 5.1). The data com-
prise eleven different studies using five different types of drugs (Levofloxacin, 
Tobramycin, Ciprofloxacin, Ciclosporin A, and Amikacin), one of them without 
liposomes (Ciclosporin A), one of them with a mixture of free and liposomal 
drug (Ciprofloxacin) and two with a liposomal formulation (liposomal Amikacin, 
liposomal Ciclosporin A). Most of the drugs were part of the treatment regimen 
for cystic fibrosis (CF) patients, but Ciclosporin A and Ciprofloxacin were in-
haled by post-lung transplant patients (prevent bronchiolitis obliterans, BOS) 
and non-CF bronchiectasis, respectively. It is also important to note, that four 
different types of nebulizers were employed, including a so-called “investiga-
tional” eFlow (Pari, Munich, Germany), a vibrating mesh nebulizer optimized by 
Pari for each of the specific drugs (used in 7 studies), as well jet nebulizers 
(Pari LC Plus, “sidestream, disposable jet nebulizer”) and an ultrasonic nebuliz-
er (Wisto Senior). Considering that all of these nebulizers have different output 
rates, droplet size distributions, delivery efficiencies, and that patients can have 
very different ways of applying/handling a nebulizer, it can be expected that for 
a given drug dose in the nebulizer, the lung-delivered dose is likely to vary by at 
least a factor of 2 [168]. 
The eleven cmax levels of the different drugs were plotted against the dose of the 
drug in the nebulizer, henceforth referred to as nominal dose (figure 5.12). 
Shapiro-Wilk test revealed a Gaussian distribution of the entire data set (p = 
0.30). The data were fitted with linear regression curves forced through zero 
(intercept = zero) and the fits were plotted for each individual drug type (dashed 
lines) and for all of the data as a whole (black line), excluding levofloxacin for 
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reasons discussed below. With R² = 0.92 for the overall fit, it can be said that 
92% of the variability of cmax can be related to the variation of the nominal 
dose). In other words, the nominal dose in the nebulizer is a strong determinant 
of the maximum plasma concentration not only for a specific type of drug, nebu-
lizer, and disease type/state but even independent of all of these parameters. 
Accordingly, one of the most important PK parameters, namely cmax, can be 
approximately predicted from  
 
with Dnom and 2.7×10-6/mL representing the nominal dose (drug dose in nebu-
lizer) and the slope of the “all data” linear regression presented in figure 5.12, 
respectively.  
The observed ratio of cmax and nominal dose (slope) varies between 1.7 ∙ 10-6 
and 3.4 ∙ 10-6 mL-1 (mL-1 = ng/mL/mg) with free and liposomal Ciprofloxacin and 
Tobramycin marking the lower and upper bound, respectively (figure 5.12). This 
2-fold spread is surprisingly small considering the expected substantial variabil-
ity induced by numerous parameters, including the use of different types of 
drugs and nebulizers as well as differences in disease type and state and profi-
ciency of nebulizer handling by the patient. For Levofloxacin, an extremely large 
slope of 7.1 ∙ 10-6 mL-1 was observed, which is more than 2-fold larger than the 
maximum slope of the other drugs. The inclusion of Levofloxacin into the overall 
(“all data”) linear regression analysis would have substantially weakened the 
quality of the linear regression analysis performed for the remaining nine stud-
ies. Possible reasons for this “poor” agreement of Levofloxacin with the other 
drugs will be discussed in the discussion section.   
 
𝑐𝑚𝑎𝑥 =  
2.7 ∙  10−6
𝑚𝐿
∙ 𝐷𝑛𝑜𝑚 (5-1) 
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Table 5.1: Summary of the maximum drug concentration cmax in the blood of patients after inha-
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b) 150 mg liposomal Ciprofloxacin + 60 mg free Ciprofloxacin 
 




Figure 5.12: The maximum plasma concentration of an inhaled drug correlates well (solid line, r 
= 0.96) with the nominal drug dose in the nebulizer (data from table 5.1). Levofloxacin was con-
sidered as outlier due to the observed high cmax levels. Shapiro-Wilk test showed the normality 
of the data. 
Table 5.1 and figure 5.12 also contain data from both liposomal CsA (L-CsA) 
and molecular CsA. For molecular CsA, the ratio of cmax to nominal dose (Dnom) 
is 1.7, which is relatively similar (1.6-fold lower) to the slope of the overall re-
gression curve (2.7). On the other hand, for L-CsA the cmax to Dnom ratio of 5.7 is 
2.2.-fold larger than the slope of the overall regression curve. Thus, the cmax 
values from both molecular and liposomal CsA can be predicted within a factor 
of 2.2 from equation 5-1.   
It is also noteworthy that the cmax to Dnom ratio for liposomal CsA is 3.4-fold larg-
er than that of molecular CsA. Thus, liposomes appear to enhance somewhat 
but not drastically lung-blood transport of hydrophilic drugs such as CsA. This 
indicates that the cmax of inhaled CsA can be predicted quite well (within a factor 
of ca. 2) from the nominal dose in the inhaler based on the slope from the over-
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dose). One hypothesis for why liposomal CsA may actually reach the blood 
faster than molecular CsA could be that liposomal CsA formulations releases 
the CsA molecules once the liposomes reach the epithelial barrier. However, it 
is not clear, if this is really what happens with liposomal CsA. In order to further 
investigate the transport mechanisms associated with liposomal CsA, fluores-
cently labeled (FRET) liposomes were manufactured and leveraged to shed 
light on this issue. 
  
5 Results  64 
 
 Manufacturing of FRET liposomes for cellular uptake studies 
In the in vitro biokinetics study with L-CsA, the concentration of the CsA mole-
cule was assessed with HPLC-MS/MS after digestion of the liposomal carrier 
with Acetonitrile. Thus, this method does not reveal if the CsA molecules are 
transported across the cell barrier as part of the liposomal carrier or as a free 
molecular drug. However, this can be assessed with fluorescently labeled lipo-
somes. 
5.3.1 Decrease of the FRET intensity after liposome lysis  
To gain more insights into cellular interaction with liposomal nanocarriers, a 
FRET (Fluorescence (or Förster) Resonance Energy Transfer) pair was incor-
porated into the lipid bilayer of liposomes. FRET occurs if a donor and acceptor 
fluorophore are in a distance between 1 – 10 nm, and the emission spectrum of 
the donor overlaps with the excitation spectrum of the acceptor fluorophore 
[174]. It was thus hypothesized that only intact liposomes would guarantee the 
prerequisites for a FRET to occur.  
To confirm the functionality of the FRET liposomes, the FRET signals prior and 
after the disintegration of the liposomes with 0.2% Triton-X100 were investigat-
ed. After nebulization of FRET liposomes into the growth medium, the medium 
was diluted with Triton-X100. A 1.2-fold dilution of the cell culture medium with 
Triton-X100 showed a statistically significant loss in FRET fluorescence intensi-
ty (excitation/emission wavelength: 505 nm/705 nm) by a factor of 4 (figure 
5.13A). Furthermore, a 5-fold and 10-fold dilution with Triton-X100 led to further 
reduction of the FRET signal (< 7%). This confirms that only intact liposomes 
have a strong FRET signal, which is the prerequisite for monitoring the structur-
al integrity of FRET liposomes. DLS measurements revealed a volume-
weighted mean diameter of 130 nm (figure 5.13B). Further, they revealed a pol-
ydispersity index (PDI) of 0.119 before the nebulization and a PDI of 0.283 after 
the nebulization, respectively (data not shown). The PDI is a direct measure for 
the distribution of the liposomes and should be below 0.3 for aerosolized deliv-
ery of liposomes [175] [176]. Taking into account the results obtained by 
Schmid et al. (2017)[68], we interpret the slight increase as deformation of the 
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liposomes during the aerosolization process. Finally, DLS measurements in the 
basal medium showed no intact liposomes after aerosolization of FRET lipo-
somes on A549-Luc(IL-8) cells, indicating a loss of liposomal integrity after cel-
lular interactions (figure 5.13C). 
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Figure 5.13: Characterization of FRET liposomes with respect to particle size and functionality. 
Panel A: Increasing lysis of FRET liposomes in suspension with increasing Triton-X100 con-
firmed the functionality of FRET liposomes, i.e., only intact liposomes provide a strong fluores-
cent signal (ex/em = 505 nm/705 nm; Dil and DiD dye) Panel B: A volume-weighted mean par-
ticle diameter of 130 nm was obtained. Panel C: The absence of particle sizes > 100 nm after 
nebulization of FRET liposomes on A549-Luc(IL-8) cells indicates a loss of liposomal integrity 
after cellular interactions. Data are presented as mean ± SEM (n = 3 independent experiments). 
** p ≤ 0.01, *** p ≤ 0.001 
5.3.2 Weak transcellular transport of intact liposomes at ALI conditions 
The degree of transbarrier transport of FRET liposomes was investigated after 
nebulization. For this, the FRET liposomes were aerosolized on A549-Luc(IL-8) 
cells on Transwell® inserts at ALI conditions (Vaerosolized = 50 µL, cell-delivered 
dose = 2.8 µg/cm²) and transbarrier transport was assessed by monitoring the 
FRET signal in the separate compartments (cell-associated, basal) for 24 h. A 
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membrane-only control (no cells) was included to evaluate the effects of the 
Transwell® insert membrane on the transport. 
While the cell-free Transwell® insert transmitted 100% of the deposited lipo-
somes into the basal medium, only ca. 23% of intact liposomes reached the 
basal medium in the presence of cells, but this within 1 h (fig. 5.14A). This is in 
disagreement with the DLS measurements (figure 5.13C), which showed no 
intact liposomes in the basal compartment after cell exposure and will be dis-
cussed later in the discussion. The fraction of intact liposomes in the cell com-
partment (after washing off of the liposomes attached apically to the cells) de-
creased from 49% to 20% within 7 h, while a similar trend, but on a much lower 
dose level, was observed for the membrane-only case (reduction from 14% to 
5% within 7 h of the liposome fraction tightly attached to the membrane) (figure 
5.14B).  On the apical side (not tightly attached to the cells or membrane), the 
initially observed liposome fraction of 44% decreased within 2 h to 9% and even 
to 3% within 24 h in the presence of cells, while no statistically significant signal 
could be observed in the absence of cells (figure 5.14C, red line). It is important 
to note that the data presented in panel A-C (figure 5.14) are normalized to the 
sum of the fluorescence intensity (at the first time point; 7 min after nebulization) 
in all compartments (basal, apical, cells/membrane) of the ALI cell culture.  
Hence, these data represent relative distributions, which add up to 100% for 
each time point; assessment of the fraction of intact liposomes relative to the 
delivered dose is not possible from these values but will be addressed in figure 
5.15.  The relatively high cell-association of intact FRET liposomes reported in 
panels B and C of figure 5.14 was confirmed with fluorescence microscopy (fig-
ure 5.14D), where the yellow areas indicate co-localization of the fluorescent 
dye Dil (red) with the actin cytoskeleton (green). 
Taken together, figure 5.14 reveals that intact liposomes were predominantly 
associated with A549-Luc(IL-8) cells and did not penetrate much (ca. 20% rela-
tive to time-dependent dose of intact liposomes; see figure 5.15) across the cell 
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Figure 5.14: Relative fraction of intact nebulized FRET liposomes in the different compartments 
of the ALI cell culture model (apical, cell/membrane, basal) consisting of a confluent layer of 
A549-Luc(IL-8) cells. Panel A: While 100% of the liposomes are transferred as intact liposomes 
across the membrane of the Transwell® insert only (no cells), only 23% of intact liposomes 
reached the basal compartment in the presence of cells. Panel B: Correspondingly, the fraction 
of intact liposomes in the cell compartment was reduced from 49% to 20% within 7 h, while this 
fraction of tightly membrane-attached liposomes reduced from 20% to 5% within 7 h in the ab-
sence of cells (membrane-only). Panel C: The fraction of cell-associated FRET liposomes de-
creased from 44% at 7 min after delivery to zero at 24 h. No apical fluorescence was detected 
for the membrane-only control (data not shown). Panel D: Relatively uniform distribution of cell-
associated intact FRET liposomes (red) overlaid with F-actin (green) and cell nuclei (blue) 
(scale bar: 10 µm). Data (A-C) are normalized to the total fluorescence intensity observed at the 
first observed time point (7 min) in all compartments (basal, apical, cells/membrane) of the 
Transwell® insert and presented as mean ± SEM (n = 3 independent experiments).  
To determine the degree of liposome degradation after deposition on the cells, 
the loss of total fluorescence intensity from all compartments was analyzed over 
time. A significant reduction in total fluorescence intensity from 100% to 74% 
was measured for 48 min (0.8 h) after the nebulization (figure 5.15A). This value 
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of fluorescence intensity was observed for the membrane-only control, which 
was almost entirely dominated by the basal compartment (figure 5.15B). This 
indicates that liposomes are stable in the cell culture medium.  Thus, the re-
duced fluorescence intensity in panel A has to be due to the degradation of lip-
osomes being in contact with cells. It is likely that the strong decrease of fluo-
rescence signal in the apical compartment is not solely due to liposome degra-
dation, but also due to transport into and through the cell compartment (into the 
basal medium). 
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Figure 5.15: Fluorescence intensity over time after nebulization of FRET liposomes onto A549-
Luc(IL-8) cells. Panel A: The total intensity significantly dropped from the initial value (set to 
100%; measured at 7 min) to 48% within the 24 h-monitoring periods for cell-covered 
Transwell® inserts. Panel B: In contrast, no statistically significant dynamics in fluorescence 
intensity was observed for the membrane-only setup. Data represent mean ± SEM (n = 3 inde-
pendent experiments). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
5.3.3 Cellular uptake of FRET liposomes by caveolae-mediated 
endocytosis 
To further analyze cellular uptake of FRET liposomes, various possible cellular 
uptake pathways were blocked with specific inhibitors, namely pinocytosis (Ami-
loride), clathrin-mediated endocytosis (Pitstop-2) and caveolae-mediated endo-
cytosis (Filipin). After a 10 min inhibition period, A549-Luc(IL-8) cells at the ALI 
were exposed to aerosolized FRET liposomes. At different time points after lip-
osome nebulization, the intact liposome fraction in the apical compartment of 
the Transwell® insert setup was measured by washing the apical compartment 
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three-times with 500 µL 0.9% NaCl, and then analyzing the wash-out for FRET 
fluorescence. The FRET fluorescence was thereafter normalized to the total 
FRET fluorescence measured in all three compartments at the first sampling 
time (7 min, i.e., 0.1 h).  
In general, there was no significant difference in FRET fluorescence for control 
(no inhibitor) and inhibited cells (figure 5.16) except for the 0.8 h time point, 
where Filipin inhibited cellular uptake, indicating that caveolae-mediated endo-
cytosis is the dominant active cellular uptake mechanism of FRET liposomes. 
The statistically significant increase in fluorescence (FRET) signal for Amiloride 
after 24 h is considered an outlier since it is unlikely that intact FRET liposomes 
will migrate back from the basal to the apical side only for one of the applied 
inhibitors, especially if we take into account that FRET liposome transport with-
out inhibitors was completed after 2 hours (see figure 5.14C).  
 






















































Figure 5.16: Investigation of cellular (A549) uptake mechanisms of aerosolized liposomes 
measured by FRET fluorescence intensity in the apical compartment after application of various 
cellular uptake inhibitors. Only Filipin showed significant inhibition after 0.8 h compared to con-
trol, indicating that caveolae-mediated endocytosis was involved in cellular uptake of FRET 
liposomes. Data are normalized to the initial fluorescence intensity after 7 min in all compart-
ments of the Transwell® insert and presented as mean ± SEM (n = 3 independent experiments). 
* p ≤ 0.05, *** p ≤ 0.001 (tested against control (black bars)) 
Further insight into the temporal profile of cellular (FRET) liposome uptake was 
obtained with live cell imaging, which focused on the apical side of the cell lay-
er. For control conditions (no inhibitor), the maximum uptake of FRET lipo-
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somes was detected after 12 min as indicated by the reduced intensity and 
patchy profile of the FRET signal (figure 5.17A) due to partial cellular uptake of 
the liposomes. These features were not observed to the same degree after ap-
plication of Filipin (figure 5.16B) confirming again the involvement of caveolae-
mediated endocytosis as an uptake pathway of FRET liposomes. Moreover, the 
appearance of micron-sized fluorescence hotspots can be interpreted as evi-
dence for gradual agglomeration of the FRET liposomes on the apical side of 
the membrane. 
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A               control, 3 min                                                         control, 12 min 
                      
B           endocytosis inhibitor, 3 min              endocytosis inhibitor, 12 min      
                      
Figure 5.17: Cellular (A549) uptake of aerosolized FRET liposomes monitored with live-cell 
imaging (red signal). Panel A: For the absence of any uptake inhibitor (control), substantial 
cellular uptake of liposomes was evident at 12 min from the reduced and patchy FRET intensity 
as compared to the 3 min image. Panel B: After inhibition of caveolae-mediated endocytosis 
(Filipin), a spatially more uniform FRET signal is found at 12 min and the appearance of “hot 
spots” is evidence for gradual agglomeration of the liposomes on the apical side of the cells. 
Scale bar: 10 µm 
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 Biokinetics of Paclitaxel loaded polymeric nanocarriers (“Ptx-
NP”)  
In addition to L-CsA, we also investigated the biokinetics of another inhaled 
nanodrug, Paclitaxel-loaded nanocarriers (Ptx-NP). Ptx-NP are currently in pre-
clinical development to treat pulmonary arterial hypertension. Since endothelial 
cells are among the main target cells of Ptx-NP, the in vitro model of the air-
blood barrier consisting of A549-Luc(IL-8) cells as epithelium was extended with 
an endothelial cell line (EA.hy926) co-cultured on the basal side of the 
Transwell® insert setup.  
Two different formulations were tested: 
• a fast-releasing Ptx-NP formulation (Ptx-NPF) 
• a slow-releasing Ptx-NP formulation (Ptx-NPS) 
5.4.1 Evaluation of dose-controllable delivery of Ptx 
Analogous to the L-CsA study, dose-controlled aerosolized delivery of Ptx-NP 
was performed with the VITROCELL® Cloud 6, which is equipped with an Aer-
oneb Pro® vibrating mesh nebulizer and a quartz crystal microbalance (QCM) 
for real-time measurement of the cell-delivered Ptx-NP dose.  
In a first step, the QCM was evaluated for its capacity to allow the prediction of 
the cell-delivered Ptx dose. This is important, since the QCM measures not only 
Ptx, but also the mass of the NPs used as nanocarrier and soluble formulation 
compounds (e.g., for pH buffering). Hence, the observed QCM signal was com-
pared to the actual Ptx dose determined by extraction of Ptx from the apical, 
cell, and basal compartment of ALI A549-Luc(IL-8) cell culture model (table 5.2) 
and subsequent Ptx dosimetry with HPLC-MS/MS. Here, 500 µL of 4% (w/v) 
Ptx-NPF suspension was nebulized on two different ALI cell culture models, 
namely a A549-Luc(IL-8) (epithelial cell line) cells and a coculture consisting of 
A549-Luc(IL-8) and EA.hy926 cells (endothelial cell line) as well as membrane-
only (no cells) as control.  
Figure 5.18 shows an exemplary real-time deposition result of the QCM after 
nebulization of 4% (w/v) fast-releasing Ptx-NPF. It is important to mention that 
the wells of the aerosolization system are filled with 13.5 mL PBS and that the 
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system was preheated to 37°C before nebulization to ensure a sufficient deposi-
tion efficiency [93]. Thus, the QCM signal monitors Ptx-NPF deposition but is 
overlaid by humidity artefacts in the system (figure 5.18, before 12 min). The 
removal of the lid after 12 min leads to drying of the QCM and a correct meas-





























Figure 5.18: Real-time monitoring of fast releasing Ptx-NPF deposition onto the quartz crystal 
microbalance (QCM) of the VITROCELL® Cloud 6 system. After aerosolization of 500 µL 4% 
(w/v) fast-releasing Ptx-NPF solution, a deposition of 133 µg/cm² (NP plus Ptx loading) on the 
QCM could be achieved. Thus, the cell-delivered dose can be assessed in real-time with the 
QCM. “Start” indicates start of nebulization. Only after removal of the lid of the exposure cham-
ber, the deposited Ptx-NP droplets dry, allowing the QCM to accurately measure the deposited 
Ptx-NP mass. 
 
From the QCM signal, which represents the mass from both the NPs and the 
Ptx, the Ptx dose can be calculated from the experimentally determined Ptx 
loading efficiency (measured routinely during Ptx-NP production phase), which 
was 4.3%. Hence, the Ptx mass dose (DPtx) can be calculated from the QCM 




𝐷𝑃𝑡𝑥 = 𝐿𝑜𝑎𝑑𝑃𝑡𝑥 ∙ 𝐷𝑄𝐶𝑀 (5-2) 
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Removal of lid 
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where LoadPtx is the Ptx loading efficiency of the nanocarriers (here 4.3%). 
It is evident from table 5.2 that the QCM-derived Ptx dose is by a factor of 1.44 
(± 11%, SD) larger than the analytically determined dose in the Transwell® in-
serts (where the cells are located). This could be interpreted as a lower effective 
loading efficiency (3.0% = 4.3%/1.44), which might occur due to artefacts intro-
duced during storage and/or transport of the formulation (from our partner Gies-
sen to Munich). However, this could also be due to differences in drug deposi-
tion onto the QCM and the Transwell® inserts (where the cells are located).  In 
any case, the relatively constant ratio of QCM and Ptx dose in the inserts (11% 
SD) allows for accurate real-time prediction of the cell-delivered Ptx dose after 
nebulization of the Ptx-NP formulation. 
In conclusion, the QCM of the VITROCELL® Cloud 6 technology could be used 
to determine the amount of drug per Transwell® insert and to allow for dose-
controlled delivery of Ptx as Ptx-NP to the cells. 
 
Table 5.2: The Ptx dose calculated from the QCM data was 44 ± 6% larger than the Ptx dose in 
the Transwell® inserts (on the cells) as determined by HPLC-MS/MS.  Since the positive bias of 
the QCM prediction is 44% (± 11% SD relative to 44%), the QCM data can serve as real-time 
dose monitor with an accuracy of 13%. Data are expressed as mean ± SEM (n = 3) 
Exposed Cells 
Measured deposition 
of the fast-releasing 
Ptx-NP formulation 
















121 ± 23 5.20 ± 0.89 3.86 ± 0.41 
Membrane-only (no 
cells)   
132 ± 21 5.68 ± 0.81 3.67 ± 0.60 
 
a. The Ptx dose on the QCM was calculated from a drug loading efficiency of 4.3% measured by our col-
leagues who manufactured the Ptx-NP formulation.  
b. The Ptx dose was assessed by HPLC-MS/MS for every compartment of the Transwell® insert setup (basal, 
cells, apical) and then summed up for comparison with the QCM-measured dose 
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5.4.2 Effects of Ptx-NP on viability and barrier integrity of the model of the 
air-blood barrier 
To ensure meaningful results from the Ptx-NP biokinetics studies, the absence 
of cellular toxicity and reduced barrier integrity is essential. Hence, these pa-
rameters were analyzed before performing biokinetics studies. 100 µL, 300 µL, 
and 500 µL of a 4% (w/v) Ptx-NP stock solution (slow and fast-releasing) in de-
ionized water were nebulized, and the deposition was assessed by the QCM. 
The cell-delivered doses were calculated in µg Ptx/cm² from the measured 
QCM mass dose and the Ptx loading of Ptx-NP ((4.8 ± 0.6)% (w/w)) according 
to equation 5-2. Aerosolized Ptx-NP (fast and slow-releasing) did not lead to 
adverse effects on barrier integrity, pro-inflammatory response, and cytotoxicity 
24 h after exposure (figure 5.19B-E and figure 5.20B-D). Furthermore, Actin 
staining of the cytoskeleton confirmed the integrity of A549-Luc(IL-8) cells after 
exposure to Ptx-NP (figure 5.17F). On the other hand, cell viability was some-
what reduced to about 50% for 6.4 µg Ptx/cm² (both formulations) (figure 5.19A, 
figure 5.20A) and for 3.8 µg Ptx/cm2 (slow-releasing only) (figure 5.20A).  
Comparable TEER values were found for the mono- and coculture (figure 
5.19D), and Ptx-NP exposure did not change the barrier integrity of the cells.  
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Figure 5.19: Effects of the fast-releasing Ptx-NPF formulation on cellular parameters (24 h 
postexposure). Panel A: No loss in metabolic activity (viability) of A549-Luc(IL-8) epithelial cells 
in a coculture with EA.hy926 endothelial cells was seen, except for the highest dose of 6.4 µg 
Ptx/cm² as compared to the sham control (vehicle). Panel B: The LDH assay showed non-
significant cytotoxic effects of the coculture model for any of the tested doses. Panel C, D: The 
dextran blue assay of the coculture model and TEER measurements indicated that Ptx-NP did 
not negatively affect the integrity of the cell barrier. Panel E: Ptx-NPF did not induce pro-
inflammatory response (IL-8 induction) of A549-Luc(IL-8) cells in a coculture with EA.hy926 
cells as compared to the sham control (TNF-α stimulation was used as positive control). Panel 
F: Actin staining (green) of the cytoskeleton of A549-Luc(IL-8) cells confirmed confluence of the 
cell layer, typical morphology of A549-Luc(IL-8) cells, and integrity of the barrier model. Scale 
bar: 10 µm. For the sham control of panel A, an outlier was removed from further statistical test-
ing. Data are presented as mean ± SEM (n = 3 independent experiments). * p ≤ 0.05, ** p ≤ 
0.01 
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Figure 5.20: Effects of the slow-releasing Ptx-NPS formulation on cellular parameters after 
24 h. Panel A: A significant decrease in metabolic activity (viability) of A549-Luc(IL-8) cells in a 
coculture with EA.hy926 cells to about 50% was observed for 3.8 µg/cm² and 6.4 µg/cm². Panel 
B: Non-significant effects on the cytotoxicity could be revealed. Panel C, D: TEER measure-
ments and dextran blue assay confirm the intact barrier integrity of the coculture model even for 
the highest dose. Data are expressed as mean ± SEM (n = 3 independent experiments). * p ≤ 
0.05 
The experiments with placebo Ptx-NP (slow-releasing) indicated that the re-
duced metabolic activity after 24 h could be attributed to the nanoparticles, not 
to the paclitaxel loading (figure 5.21). In the placebo experiments, similar doses 
as compared to the verum exposure were used (presented as Ptxeq, eq = 
equivalent). 






























































Figure 5.21: Effect of placebo slow-releasing Ptx-NPS on the metabolic activity of A549-Luc(IL-
8) cells. A significant decrease in metabolic activity (cell viability) could be observed after 24 h. 
Hence, the observed loss in viability for Ptx-loaded NP is due to the polymeric nanocarrier (for 
the highest two doses; see figure 5.20 A). Data are expressed as mean ± SEM (n = 3 inde-
pendent experiments). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
Since the barrier integrity was not impaired, but high doses are expected to be 
needed for efficacy studies, the Ptx-NP biokinetics studies were performed for 
the highest dose level (ca. 6.4 µg Ptx/cm2). On the other hand, for this dose, 
reduced metabolic activity was found after 24 h, which might affect cellular up-
take and/or transcellular transport. However, most of the NP-Ptx transport oc-
curs during the first 2 h after exposure (see below), which did not show any re-
duction in cell viability (figure 5.22). Thus, 6.4 µg Ptx/cm2 was considered a 
suitable dose level for both biokinetics and efficacy studies. 
 







































Figure 5.22: Effect of slow-releasing Ptx-NPS on the metabolic activity of A549-Luc(IL-8) cells 
after 2 h. There was no reduction in metabolic activity. Data are expressed as mean ± SEM (n = 
3 independent experiments) 
5.4.3 Transbarrier transport of Ptx-NP for the mono- and coculture model 
of the air-blood barrier 
Similar to the L-CsA biokinetics study, Ptx-NPF and Ptx-NPS were nebulized on 
two in vitro models of the air-blood barrier. The influence of the Transwell® in-
sert membrane on the biokinetics was accounted for as described in the meth-
ods (equation 1-3). The doses were normalized to the cell-delivered Ptx dose 
per Transwell® insert (100% = (21 ± 2) µg Ptx), but ca. 15% of this dose was 
already transported to the basal medium in the VITROCELL® Cloud system, 
i.e., prior to starting the biokinetics study in a separate multiwall plate. 
The biokinetics of both Ptx-NP formulations revealed a burst-like increase for 
both cell models (figure 5.21), which means that steep initial transport rates into 
the basal compartment were obtained 4 h after aerosolization. Then, the 
transport was flattening as almost all of the available Ptx has been transported 
into the basal compartment.  
No significant difference in the translocation profile was observed for both cell 
models (epithelial A549-Luc(IL-8) and coculture model (A549-Luc(IL-8) and en-
dothelial EA.hy926 cells) for both Ptx-NP formulations, except for slow-releasing 
Ptx-NPS under monoculture conditions (figure 5.23C), which showed a ca. 2-
fold reduced transbarrier transport (ca. 30%, blue line) and corresponding high-
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er Ptx storage in the cell-apical compartment of ca. 70% as compared to ca. 
30% for all other cases (figure 5.23A, B & D, green line). 
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Figure 5.23: Biokinetics of two different aerosolized Ptx-NP formulations in two cell culture 
models expressed as the temporal profile of the Ptx dose in the cell plus apical compartment 
and the basal compartment (transbarrier transport). Panel A, B: For the fast-releasing Ptx-NPF, 
65% of the Ptx dose is transported across the barrier within 2 h without significant dependence 
on the type of cell culture. Panel C:  For the slow-releasing Ptx-NPS in the monoculture model, 
the transbarrier transport was about 2-fold reduced (to ca. 30%) as compared to Ptx-NPF (pan-
els A and B). Panel D: The same biokinetics profile as in panels A & B (for Ptx-NPF) was ob-
served for the slow-releasing Ptx-NPS in the coculture model. Data are normalized to the deliv-
ered Ptx dose per Transwell® insert ((21 ± 2) µg) and expressed as mean ± SEM (n = 3 inde-
pendent experiments). 
As demonstrated by this biokinetics study, the addition of an endothelial cell line 
on the basal side of the Transwell® insert did not increase the barrier tightness 
of the cell culture model with respect to Ptx-NP (figure 5.23). This was further 
investigated by analysis of dextran blue translocation as a paracellular transport 
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marker, which was routinely measured for each of the Ptx-NP exposures prior 
to Ptx-NP application. The presence of endothelial cells (EA.hy926) increased 






























































Figure 5.24: Investigation of the dependence of paracellular transport on mono- (A549) and 
coculture cell culture model (A549 & EA.hy926) based on dextran blue transport into the basal 
compartment (within 2h).  The presence of endothelial cells (EA.hy926) increases paracellular 
transport from (1.5 ± 0.2)% to (5.4 ± 0.5)%. Data are expressed as mean ± SEM (n = 12 inde-
pendent experiments). **** p ≤ 0.0001 
Thus, inclusion of an endothelial cell line (EA.hy926) did not substantially affect 
the barrier permeability of A549 cells, neither for Ptx-NP (no significant effect) 
nor for paracellular transport (moderate decrease).  
In conclusion, burst-like transport profiles of both types of Ptx-NP formulations 
(fast and slow release) were observed reaching an asymptotic transport value 
of ca. 70% (30% retained by cells) without significant difference between the 
monoculture and coculture model, except for the low transport of Ptx-NP (only 
30% transport across cell barrier). 
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5.4.4 Extension to the coculture model leads to enhanced storage of Ptx 
The assessment of the biokinetics revealed the storage of Ptx in the apical and 
cell compartment even after 24 h. For a more in-depth analysis of the Ptx frac-
tion, which was taken up by the cells, the loosely attached Ptx fraction (apical) 
was removed via several washing and freeze-thaw cycles as described in the 
method section. The membrane attached Ptx fraction was subtracted to account 
for membrane artefacts. For these experiments, the measured Ptx dose was 
normalized to the cell-delivered Ptx dose (100% = (21 ± 2) µg). 
The experiments showed that the addition of endothelial cells significantly in-
creased the intracellular Ptx storage after Ptx-NP exposure for every investigat-
ed time point (figure 5.25A,B, grey bars). In addition, slow-releasing Ptx-NPS 
showed superiority in terms of intracellular drug accumulation as Ptx was pre-
sent for every investigated time point and as the stored fraction after 24 h was 
1.7-fold increased. Overall, the results indicate that endothelial cells led to addi-
tional Ptx transport, which increased the cellular Ptx storage.  
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Figure 5.25: Storage of Ptx in the cell-compartment of the coculture model after the nebuliza-
tion of fast- and slow-releasing Ptx-NP formulations. The cellular Ptx dose is larger for the co-
culture model, especially for the intermediate time points (0.5 and 2h), where this trend is statis-
tically significant for one of the two formulations each. The onset of Ptx accumulation in the cells 
started earlier for slow-releasing Ptx-NPS. The cell-retained Ptx fraction was preferentially found 
in the endothelial cells, which are target cells for the treatment of pulmonary hypertension. Data 
are normalized to the delivered Ptx dose per Transwell® insert ((21 ± 2) µg) and expressed as 
mean ± SEM (n = 3 independent experiments). * p ≤ 0.05 
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5.4.5 Particle size analysis of Ptx-NP 
Further investigation of the biokinetic fate of slow-releasing Ptx-NP in the A549-
Luc(IL-8) epithelial barrier model was performed by measurements of the vol-
ume-weighted size distribution of aerosolized Ptx-NP by dynamic light scatter-
ing (DLS) in the apical and basal compartment. Intact Ptx-NP with a typical di-
ameter of ca. 200 nm were found in the apical compartment for up to 2 h, but 
not at 24 h anymore (figure 5.26A). In contrast, no intact Ptx-NP of ca. 200 nm 
were found in the basal compartment (figure 5.26B). The particles with a size of 
5 – 8 nm in the basolateral medium is consistent with the presence of fetal calf 
serum in the cell culture medium (figure 5.26D). In contrast to cell-covered 
Transwell® insert membranes, the transport across a membrane-only control 
revealed intact nanocarriers in the basolateral medium (figure 5.26C). Thus, the 
A549 cell barrier appears to be impermeable by Ptx-NP. On the other hand, Ptx 
was found in the basolateral medium (figure 5.23 and 5.25), which suggests 
that Ptx is released from the nanocarriers. 
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Figure 5.26: Further investigation of slow-releasing Ptx-NPS transbarrier transport by (volume-
weighted) DLS size distribution measurements on the apical and basal side of A549-Luc(IL-8) 
cells. Panel A: 200 nm Ptx-NP (DLS size measurement) were found for up to 2 h on the apical 
side of the cells. Panel B: No evidence for 200 nm Ptx-NP was found in the basal compartment. 
Panel C: Transport of intact nanocarriers (NP) into the basal medium (mean diameter: 239 nm) 
was observed for the membrane-only control (after 24 h). Panel D: DLS size measurement of 
the growth medium (including fetal calf serum) without any NPs revealed the presence of pro-
teins with a typical particle diameter of 8 nm. Data in panels A and B are expressed as mean ± 
SEM (n = 3 triplicates). 
5.4.6 Caveolae-mediated endocytosis as the uptake mechanism of Ptx-NP 
It was shown that while nanocarriers themselves were not transported across 
A549-Luc(IL-8) cells, Ptx molecules were. Hence it is conceivable, that intact 
nanocarriers were taken up the cells via one of the endocytosis uptake path-
ways and subsequently Ptx was released from the cells into the basolateral 
medium. Various cell uptake inhibitors (Filipin, Amiloride, and Pitstop-2) were 
used to identify such a pathway for fast-releasing Ptx-NPF (35 µg/cm²; here 
loaded with Rhodamine dye instead of Ptx), analogues to the FRET liposome 
cellular uptake study. 
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For Amiloride and Pitstop-2 treated cells, the decrease of fluorescence intensity 
in the apical compartment due to uptake and transport into the basal medium 
did not differ significantly from the control (figure 5.27A, black bars). Conse-
quently, the pathways that were blocked by Amiloride (pinocytosis) and Pitstop-
2 (clathrin-mediated endocytosis), respectively, were not involved in the uptake 
of fast releasing Ptx-NPF. In contrast to this, an increase in the fluorescence 
was measured for the cells that were inhibited by Filipin (figure 5.27B, blue line). 
This indicated caveolae-mediated endocytosis as the uptake mechanism of Ptx-
NP by A549-Luc(IL-8) cells. In combination with the obtained DLS results, it 
could be shown that cellular uptake into the cells was facilitated by caveolae-
mediated endocytosis of the nanocarriers, but Ptx transport into the blood (here 
basal medium) required a release of Ptx from the nanocarriers. Hence, the 
nanocarriers themselves were not transported across the barrier built by A549-
Luc(IL-8) cells.  
The Filipin experiments were also conducted for the coculture model of the air-
blood barrier. Here, no significant differences in comparison to the control were 
revealed (figure 5.27C). In consideration of the observed higher paracellular 
transport for dextran blue by the coculture model, this result showed that the 
addition of the endothelial cell line led to additional transport. 
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Figure 5.27:  Investigation of endocytic cellular uptake mechanisms for fast releasing Ptx-NP. 
Panel A, B: The removal of (fast-releasing) Ptx-NPF (35 µg/cm²; Rhodamine loaded) from the 
apical side of A549-Luc(IL-8) cells showed the cellular uptake kinetics. Similar to Figure 5.21, 
the asymptotic dose of ca. 20% was achieved within 2 h after exposure. Inhibition of various 
types of endocytic uptake with specific inhibitors revealed that caveolae-mediated endocytosis, 
which is blocked by Filipin, governed the cellular uptake of Ptx-NP. Panel C: The epithelial-
endothelial coculture model displayed no effect of Filipin on removal of Ptx-NPF from the apical 
compartment indicating that additional transport routes by endothelial cells were involved. Data 
in panels B and C are normalized to the initial rhodamine fluorescence in all compartments (ba-
sal, apical, cells/membrane) and expressed as mean ± SEM (n = 3 independent experiments). * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (tested against control, black bars) 
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5.4.7 Efficacy of Ptx-NP 
As Ptx-NP are currently in preclinical development as therapeutic option against 
pulmonary arterial hypertension (PAH), their effect on PAH-relevant genes 
(FOXO1A, FOXO3A, GADD45, and SOD2) was investigated. As the EA.hy926 
cell line expresses these genes, this cell line served as target to investigate the 
efficacy. Shortly, slow-releasing Ptx-NP were aerosolized at not to low toxicity 
doses (1.4 – 6.4 Ptx/cm2; see figure 5.20) onto the coculture model of A549-
Luc(IL-8)/EA.hy926 cells. The RNA of EA.hy926 cells on the basal side of the 
Transwell® insert was isolated and analyzed by qPCR for mRNA regulation as 
compared to sham control.  
qPCR analysis revealed that FOXO1 and FOXO3 expression were upregulated 
in a dose-dependent manner (figure 5.28A,B). Furthermore, a ca. two-fold in-
crease of the GADD45 gene could be noted even for the lowest dose (figure 
5.28C) and SOD2 was upregulated in a dose-dependent manner reaching a ca. 
two-fold upregulation for the highest dose of 6.4 µg Ptx/cm² (figure 5.28D).  
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Figure 5.28: qPCR analysis of EA.hy926 RNA isolated from the coculture model (all values are 
presented relative to PBGD as housekeeping gene). Panel A, B: FOX transcription factors were 
activated by the treatment with slow-releasing Ptx-NP. Panel C, D: Furthermore, pro-apoptotic 
genes were upregulated. Data are expressed as mean ± SEM (n = 3 independent experiments). 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
5.4.8 Comparison of transbarrier transport rates at submerged and ALI 
conditions 
All studies with Ptx-NP were carried out at ALI conditions. However, most pre-
clinical in vitro studies are performed under submerged culture conditions, i.e., 
the cells are completely covered with medium on the apical side. While for poor-
ly polarizing cells such as A549 cells, this is likely not affecting the drug efficacy 
and toxicity if the dose is expressed in terms of mass per surface area (as done 
here; Lenz et al., 2014 [89]), it has been shown that cell culture conditions can 
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substantially affect the biokinetics of both molecular [74], and nanocarrier based 
drugs [68]. 
Similar to the Ptx-NP biokinetics study described above, slow-releasing Ptx-NP 
were nebulized onto A549-Luc(IL-8) at ALI conditions and the cell deposited 
dose was assessed by the QCM (7 µg Ptx/cm²; 4.8% loading efficiency of Ptx-
NP. The same dose was pipetted and mixed into the apical medium of A549-
Luc(IL-8) cultured at submerged conditions. A graphical depiction of both ap-
proaches is presented in figure 5.29A. 
Both setups showed remarkable differences in the transport profile. At sub-
merged conditions, only (10 ± 11)% of the total Ptx reached the basal compart-
ment, indicating that the majority of Ptx-NP (74 ± 19)% remained in the apical 
medium (figure 5.29B). At ALI conditions, where Ptx-NP were nebulized on the 
cells, (51 ± 21)% of the total Ptx reached the basal compartment after 24 h. 
Consequently, the apical-to-basal transport of Ptx after aerosolization was en-
hanced by a factor of 5 as compared to submerged conditions. This could at 
least in part be due to the fact that nanoparticles are suspended in a relatively 
thick column of cell culture medium (here 0.48 cm) as compared to ALI condi-
tions (ca. 25 µm [68]), and may not reach the cells within the available incuba-
tion time.  
To explore this issue, an in silico sedimentation, diffusion and dosimetry (ISDD) 
model described by Hinderliter et al. (2010) [164] was used to calculate the cell 
delivered dose fraction of Ptx-NP. Assuming an effective particle density of 
1.25 g/cm³ for Ptx-NP [165] and a volume mean diameter of 260 nm, this model 
predicted that only 25% of the Ptx-NP, which are suspended in the apical medi-
um, actually reach the cells within 24 h (figure 5.29C). With this information, the 
dependence of cell metabolic activity (WST-1) on cell-delivered dose could be 
determined for both ALI and submerged culture conditions. At submerged con-
ditions, a dose of 9.2 µg Ptx/cm² was necessary to reduce the viability by 50% 
(figure 5.29D). On the other hand, a cell-delivered dose of 3.5 µg Ptx/cm² de-
creased the metabolic activity of ALI cultured cells by 50%. This shows that Ptx-
NP are 2.6-fold more toxic under ALI conditions.   
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Figure 5.29: Comparison of slow-releasing Ptx-NPS transport across A549-Luc(IL-8) cultured 
at submerged and ALI conditions. Panel A: At submerged conditions, cells were covered with 
growth medium containing Ptx-NP (dose = 7 µg Ptx/cm²). In contrast to this, the same dose of 
Ptx-NP was aerosolized onto cells at ALI conditions. Panel B: Assessment of the fractional Ptx 
dose showed a weak transport of Ptx-NP (10 %) to the basal compartment at submerged condi-
tions after 24 hours. On the other hand, the corresponding dose at ALI conditions was 5-fold 
higher. Data are normalized to the total Ptx dose (29.8 µg). Panel C: The deposition fraction at 
submerged conditions was modeled by an in silico sedimentation, diffusion, and dosimetry 
model (ISDD) [164]. Assuming an effective particle density of 1.25 g/cm³ for Ptx-NP [165] and a 
volume mean diameter of 260 nm, only 25% of the total (nominal) Ptx-NP in the apical medium 
deposited on the cells within 24 h. Panel D: Dose-response curve for metabolic activity (WST-1) 
at ALI and submerged conditions (taking this low cell-delivered dose fraction of 25% of nominal 
dose into account) The dose to achieve a 50% loss in metabolic activity (EC50) was 
3.5 µgPtx/cm² and  9.2 µg/cm² at ALI and submerged conditions, respectively. Data in panels B 
and D are expressed as mean ± SEM (n = 2 (panel B) – 3 (panel D) independent experiments). 
apical 
basal 
 basal  
Submerged: 
vs. 
Air-liquid interface (ALI): 
Ptx-NP 
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5.4.9 Transbarrier transport of Ptx-NP in an in vitro PH disease model  
All of the in vitro data presented above are based on healthy cell models of the 
lung without induced disease phenotype. On the other hand, in clinical settings, 
drugs are inhaled by patients. Hence, it is important to also perform in vitro drug 
testing in in vitro disease models.  
For Ptx-NP, the relevant disease model is pulmonary arterial hypertension 
(PAH). To establish an in vitro PAH disease model, which is as described in the 
literature [19], the endothelial cell line EA.hy926 was challenged with TNF-α for 
24 h prior to co-culturing it with healthy epithelial cells (A549-Luc(IL-8)) as de-
scribed in the methods section (4.1). This TNF-α treatment of EA.hy926 cells 
leads to proinflammatory stimulation, which results in a decrease of TEER val-
ues and an increase of permeability [177].  
For characterization of the effect of TNF-α challenge on endothelial barrier in-
tegrity, this issue was investigated prior to adding the A549-Luc(IL-8), i.e. im-
mediately after the 24 h incubation with TNF-α and 2 h attachment to the basal 
side of the Transwell® insert. TNF-α challenge significantly disrupted the endo-
thelial barrier integrity as evidenced by the dose-dependent increase in the en-
dothelial paracellular permeability reaching a 2.7-fold increase (relative to TNF-
α = 0) at the highest dose of 18 ng/cm² TNF-α (figure 5.30A). On the other 
hand, the metabolic activity of EA.hy926 cells was not substantially impaired 
due to TNF-α challenge  (figure 5.30C), which is essential for the conduction of 
reliable biokinetics studies.  
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Figure 5.30: PAH-like modeling of endothelial dysfunction in vitro using a TNF-α challenge 
model described in the literature. Panel A: Dose-dependent increase of endothelial paracellular 
permeability one day after TNF-α treatment was observed. Panel B: TNF-α did not decrease 
the metabolic activity of the cells in a dose-dependent manner.  Data are expressed as mean ± 
SEM (n = 3 independent experiments). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
The changes in endothelial barrier integrity were also substantiated by Actin-
DAPI staining and fluorescence microscopy. Contrary to the control (no TNF-α 
addition), 18 ng/cm² TNF-α treatment led to a loss in the cellular connectivity as 
evidenced by the less intense and less sharp actin signal at cell-cell contacts 
(figure 5.31).  
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Figure 5.31: Fluorescence imaging of Actin-DAPI stained of EA.hy926 cells 24 h after TNF-α 
addition (18 ng/cm²) that led to morphological changes and a loss of cellular connectivity (less 
sharp actin signal at cell-cell contacts) in contrast to the control. Actin (cytoskeleton): green; 
DAPI (nucleus): blue Scale bar: 10 µm 
For conduction of Ptx-NP biokinetics studies, the TNF-α challenged endothelial 
cells were integrated into a coculture system with “healthy” A549-Luc(IL-8) cells 
as described in the methods section (see section 4.1). Similar to the dextran 
blue (dye) analysis of inflammatory stimulated (TNF-α challenged) EA.hy926 
cells alone, quantitative fluorescence spectroscopy was used to monitor trans-
location of the dye across the diseased coculture barrier model. The analysis 
revealed an even more pronounced dose-dependent increase of paracellular 
permeability by a factor of 2.5 and 5.8 for 9 ng/cm² and 18 ng/cm² TNF-α, re-
spectively (figure 5.32A). This is consistent with the PAH-phenotypic feature of 
increased “leakiness” of the air-blood barrier [178].  
To investigate possible effects of disease state on the biokinetics of Ptx-NP, 
slow-releasing Ptx-NP were aerosolized on the diseased coculture (cell-
delivered dose 135.3 µg/cm², which corresponds to 5.8 µg Ptx/cm²), and the Ptx 
concentration in each compartment was assessed via HPLC for an incubation 
period of 24 h. This showed that there was no statistically significant effect of 
disease state on the apical/cell-associated Ptx dose during the various time 
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up to 5.8-fold enhanced paracellular transport for the disease model (figure 
5.32A), no increase in Ptx transport out of the apical/cell into the basal com-
partment (= 1 – apical/cell dose fraction) was observed for any of the investi-
gated time points. This implies that also the transbarrier transport of Ptx was not 
affected by the disease state.  
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Figure 5.32: Assessment of barrier integrity of and (slow release) Ptx-NP biokinetics across the 
diseased (TNF-α challenged) epithelial-endothelial coculture (control = endothelial EA.hy926 
cells without TNF-α challenge). Panel A: Relative dextran blue translocation after 24 h. The 
paracellular permeability of the diseased coculture model was significantly (up to 5.8-fold) in-
creased as compared to healthy control. Panel B: Biokinetics of slow-releasing Ptx-NPS. No 
statistically significant reduction in Ptx storage in the combined apical and cell compartment 
could be measured for the diseased coculture, which also implies that the basal Ptx dose 
(trasnbarrier transport) is not affected by the disease state. Data are normalized to the delivered 
Ptx dose per Transwell® insert ((24 ± 1) µg) and expressed as mean ± SEM (n = 3 independent 
experiments). * p ≤ 0.05 
 Application of the in vitro-based in silico PBPK model for the 
prediction of the in vivo PK of Ptx 
In section 5.1.4, two in silico PBPK models were described, which showed pre-
dictive capacity for the CsA concentration in the blood of post-lung transplanta-
tion patients (PK profile), if the lung-to-blood transport rate was determined ex-
perimentally with our in vitro ALI epithelial cell barrier model (A549 cells) com-
bined with aerosolize L-CsA delivery. The simple discrete model is now applied 
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to predict the PBPK profile of inhaled Ptx-NP in clinical settings based on the in 
vitro biokinetics data for Ptx reported in chapter 5.4.3. Analogous to the L-CsA 
study, the following model structure was used: 
 
1) Lung compartment with Ptx-NP deposition after inhalation 
2) Blood compartment with lung-to-blood transport rate for Ptx, leading to 
an influx of Ptx into the blood 
3) Loss (removal) compartment inducing depletion of Ptx in the blood as a 
result of metabolic Ptx degradation and/or excretion 
 
For step 1), typically observed peripheral lung deposition values were used 
(10%, 20%, and 40% relative to an assumed nominal dose of 10 mg in the in-
haler) to assess how patient- and device-specific uncertainties in lung-deposited 
dose fraction affect the predicted cmax levels.  
For step 2), kLB was calculated for each time layer by dividing the fractional 
change in basal Ptx dose of adjacent measurement points by the corresponding 
time interval, analogous to the L-CsA study. Transport rates (table 5.3) were 
derived from a fit curve through the Ptx-NP biokinetics as presented in chapter 
5.4.3 (Ptx-NPF: tb = (0.5 – 11.9) * exp(-0.6*t) + 11.9, r² > 0.98; Ptx-NPS: tb = (-
1.3 - 5.5) * exp(-1.9 * t) + 5.5, r² > 0.99). 
 
Table 5.3: Transport rates for both Ptx-NP formulations, calculated from figure 5.23A,C.  
time (h) kLB for Ptx-NPF (1/h) kLB for Ptx-NPS (1/h) 
0 0.000 0.000 
0.25 0.567 0.300 
0.5 0.472 0.410 
1 0.346 0.227 
2 0.317 0.063 
4 0.175 0.005 
8 0.036 0.000 
12 0.003 0.000 
24 0.000 0.000 
 
These transport rates were then used to calculate the lung to blood transported 
Ptx dose. To describe the depletion of Ptx in the blood compartment as a result 
of metabolic Ptx degradation and/or excretion for step 3), a Ptx PK study con-
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ducted by Huizing et al. (1995) was used, where Ptx was administered intrave-
nously to patients [179]. Here, a mean fractional loss rate kloss of 0.41/h was 
derived from the PK. A summary of the applied parameters is provided in figure 
5.33A. 
The modeled PK profile predicts a cmax level of (17.6 ± 5.4) ng/mL after inhala-
tion of 10 mg fast releasing Ptx-NPF and a peripheral lung deposition of 10% 
(figure 5.33B). For the slow-releasing Ptx-NPS, the model predicts cmax levels of 
9.3 ± 2.8) ng/mL assuming a lung deposition fraction of 10% and a nominal 
dose of 10 mg (figure 5.33C). For both of the formulations, a 20% and a 40% 
peripheral lung deposition led to 2-fold and 4-fold, respectively, increased cmax 
level (figure 5.33D), which indicates that the nominal dose is a linear determi-
nant of cmax levels. 
  










B               C                 
  
D 
Lung deposition fraction cmax for Ptx-NPF (ng/mL) cmax for Ptx-NPS (ng/mL) 
0.10 17.6 ± 5.2 9.3 ± 2.8 
0.20 35.2 ± 10.3 18.7 ± 5.3 
0.40 70.5 ± 20.7 37.3 ± 10.6 
 
Figure 5.33: Application of the in vitro-based in silico PBPK model for the prediction of the in 
vivo PK of Ptx. Panel A: Scheme of our simple discrete PBPK model introduced in section 
5.1.4. Experimentally determined in vitro transport rates (kLB) of both types of inhaled Ptx-NP 
formulations were used to calculate the Ptx PK profile in humans. Panel B, C: Predicted Ptx PK 
levels (dots) for a nominal Ptx-NP dose of 10 mg and an assumed peripheral lung deposition of 
10% based on our simple discrete in silico model, which includes in vitro cellular transport rates 
of Ptx-NP. Inhalation of fast-releasing Ptx-NPF led to 1.9-fold increased systemic Ptx levels as 
compared to slow-releasing Ptx-NPS. Panel D: cmax linearly scales with the lung deposition 
fraction for both types of inhaled Ptx-NP. 
Error bars for the modeled data were calculated applying Gaussian error propagation on the in 
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6 Discussion 
The human lung presents an interface between air and blood. From a clinical 
point of view, this provides a significant advantage as lung diseases can directly 
be targeted by inhalation therapy. However, several clearance processes in the 
lung decrease the dose of inhaled drugs, e.g., lung-to-blood transport of drugs 
by the lung epithelium. Consequently, epithelial permeability for drugs is one of 
the parameters, which influences the lung retained dose and determines the 
success of inhalation therapy.  
To assess epithelial permeability in vitro, Transwell® insert-cultured lung cell 
epithelial lines are a prominent model, where the apical compartment repre-
sents the side of the lung, which is exposed to inhaled drugs, and the basal side 
the blood. Recent studies have shown that this model can be utilized to deliver 
relevant results, which bridge the gaps between in vivo and in vitro, and show 
the potential to ensure “the principles of the 3Rs (replacement, refinement, re-
duction)” of animal experiments [24]. For example, the model could be used to 
find optimized drug formulations in terms of increased lung tissue retention [73]. 
Further, in vitro apical-to-basal transport rates of gold nanoparticles were suc-
cessfully combined with PBPK modeling to ultimately predict the gold nanopar-
ticle levels in various rat organs [52]. Moreover, it was shown that the drug dis-
tribution in the different compartments (apical, cells, and basal) of the model 
after drug exposure can serve as an estimation of the drug dose in the lung af-
ter inhalation [68]. 
Overall, these studies significantly increased the clinical relevance of Transwell® 
insert models in terms of expectable dose ranges in vivo and selection of supe-
rior formulations for inhalation therapy. However, up to now, they do not provide 
quantitative in vivo translation of dose-response curves. We utilized the model 
to translate apical-to-basal transport rates of two nanodrugs (liposomal Ciclo-
sporin A (L-CsA) and Paclitaxel-laden co-polymeric nanoparticles (Ptx-NP)) into 
pharmacokinetics profiles (human), aiming to answer: 
• How do nanodrugs interact with lung epithelial cells and how are they trans-
ported? 
• How do inflammatory conditions in the lung affect the transport of 
nanodrugs? 
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• How do different culture conditions (air-liquid interface vs. submerged cell 
culture) affect the efficacy and toxicity of the nanodrugs? 
In the following, the obtained results to answer the questions will be discussed. 
The discussion will highlight the importance of air-liquid interface cell culture to 
simulate inhalation therapy in vitro, will clarify the interactions of L-CsA and Ptx-
NP with lung epithelial cells, and, overall, will discuss the clinical relevance of 
our results. 
 ALI culture conditions are more physiological than submerged 
conditions 
Traditionally, in vitro cell models of the lung have been cultured under sub-
merged conditions. While this may be acceptable for interstitial cell types, it is 
not physiologic for lung epithelial cells, which form the air-tissue/liquid barrier in 
the lung [31].  
The more biomimetic features of ALI models of the air-blood barrier have been 
discussed extensively in the literature [62, 63, 180]. Among others, ALI condi-
tions allow the setup of more complex up and realistic to quadruple coculture 
models (e.g., macrophages, epithelial cells, fibroblasts, dendritic cells and/or 
endothelial cells) [78, 181], maintenance of epithelial lining fluids (e.g., lung sur-
factant) [79], aerosolized drug delivery directly onto the epithelium, and real-
time measurement of the cell-delivered drug dose (e.g., quartz crystal microbal-
ance) [88, 89, 93]. Especially the latter two aspects are highly relevant for bioki-
netics studies of nanodrugs as performed here since rapid and direct contact 
between nanodrugs and epithelial cells mimics the exposure scenario during 
inhalation therapy and cannot be obtained under submerged cell culture condi-
tions where the nanoparticles (nanodrugs) are suspended in the medium for an 
extended period of time (more than 24 h depending on particle size, density, 
and medium height) due to low diffusivity and settling speed of nanodrugs in cell 
culture medium [164]. Albeit there have been comparisons of transbarrier 
transport and toxicity/efficacy of molecular drugs and nanoparticles under sub-
merged and ALI culture conditions [74, 89, 182, 183], not much evidence has 
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been provided for pharmacokinetics, efficacy and toxicity studies with 
nanodrugs, yet. 
We found significant differences in the nanodrug transport between both culture 
conditions. Ptx-NP were not reaching the cells as rapidly as molecular Ptx due 
to the high diffusivity of molecules (< 10 nm in diameter) as compared to 
> 100 nm NPs. This was confirmed by combined DLS (size) measurement and 
ISDD particokinetics modeling described by Hinderliter et al., 2010 [164]. The 
model was used to predict the deposition fraction of Ptx-NP on submerged cul-
tured cells. After 24 h, only 25% Ptx-NP deposited on the cells, indicating strong 
interactions with media ingredients. On the other hand, ALI cell exposure ena-
bled direct deposition of the Ptx-NP onto the epithelial cells allowing immediate 
nanodrug-cell contact as experience during inhalation therapy in the lung. This 
will result in higher transbarrier transport rates for nanodrugs. This can be seen 
by comparing the transport rate and duration of transport of L-CsA reported for 
ALI conditions (this study) with those under submerged cell culture conditions 
compartment [73]. The transport rate and duration of L-CsA transbarrier 
transport at ALI is 1.42/h and 2 h, respectively, as compared to 0.007/h and > 
24 h (largest observed time point) reported for submerged culture conditions 
[73]. Thus, ALI conditions provide 200-fold higher dose rates and much shorter 
transbarrier transport periods. This phenomenon is often referred to as a “burst-
like” transport profile (high rate, short duration), which is consistent with the L-
CsA PK profile observed in clinical settings [17, 68, 166]. 
Another difference in ALI vs. submerged culture conditions concerns the onset 
of toxicity after Ptx-NP exposure. In this study, A549-Luc(IL-8) cells responded 
more vulnerable to Ptx-NP under ALI conditions (2.6-fold lower EC50 value for 
WST-1 assay) as compared to pipetted Ptx-NP at submerged conditions. This 
may be due to the strong interactions of Ptx-NP with media ingredients under 
submerged conditions, which could prevent direct nanodrug-cell interactions.  
Thus, ALI cell culture conditions are crucial for both pharmacokinetics as well as 
efficacy/toxicity studies. 
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 Evaluation of dose-controllable delivery of aerosolized 
nanodrugs 
To transfer in vitro results into the clinical setting (dose finding), assessment of 
the cell-delivered drug dose is an essential step. In standard submerged cell 
culture systems, typically the nominal drug concentration in the medium is re-
ported, which can be readily converted into dose by multiplication with the vol-
ume of the cell culture medium. This approach is correct for molecular drugs, 
since drug molecules are small (<10 nm in diameter) and highly diffusive [86], 
which gets them into contact with the cells almost immediately (within minutes). 
For ca. 100 nm nanodrugs, their mobility due to diffusion (and sedimentation) is 
extremely slow resulting in only ca. 25% of the administered drug dose reaching 
the cells within 24 h (figure 5.29C). Hence, preclinical testing of nanodrugs is 
difficult with standard submerged cell culture systems, since the cell-delivered 
dose is highly uncertain. 
To overcome this issue, we used the VITROCELL® Cloud 6 technology to deliv-
er L-CsA and Ptx-NP to the in vitro cell-models in aerosolized form. Previous 
studies have shown that the VITROCELL® Cloud 6 QCM can be used for accu-
rate measurement of the cell-delivered doses of various types of nanoparticles 
with an accuracy of 3.4% [93]. We also found that the QCM of the Cloud system 
could reliably measure the cell-delivered drug dose. For both types of drugs, 
there was a linear correlation (r > 0.98) between QCM-measured cellular dose 
and nanodrug concentration in the nebulizer (for a constant volume of nanodrug 
suspension) over a wide dose range (1 – 70 µg/cm² for L-CsA, 4.5 – 113 µg/cm² 
for Ptx-NP). Consequently, the desired cell-delivered nanodrug dose can be 
selected by adequate dilution of the nanodrug suspension. 
However, for Ptx-NP, a large difference of 45% between analytically (HPLC) 
determined drug dose on the cells (in the Transwell® insert) and QCM-derived 
molecular drug dose was found, which is larger than typically reported 10 – 20% 
difference for fluorescent tracers or nanoparticles [93]. This is due to the fact 
that with nanocarriers additional uncertainties are introduced, especially a rela-
tively large uncertainty in nanocarrier loading and efficiency. Based on previous 
work at the HMGU (Schmid lab), we estimate the upper limit of systematic er-
rors in the following key experimental parameters: loading efficiency (10%), 
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combined QCM and HPLC measurement accuracy (10%), deviation between 
insert- and QCM deposited dose (15%), and retrieval efficiency of Ptx from the 
three compartments of the insert (20%). Based on this, the upper limit for exper-
imentally observed differences between QCM and insert dose of Ptx is 55%, 
i.e., the measured difference of 45% is still within acceptable experimental un-
certainties.  
Hence, it can be concluded that the QCM is capable of measuring the cell-
delivered dose of drugs loaded into nanocarrier systems, albeit with potentially 
relatively low accuracy. All in all, QCMs allow real-time measurement of the cell-
delivered drug dose, which enhances data quality and alleviates the need for 
more complex dosimetric analyses such as HPLC-MS/MS measurements. 
 In vitro cellular uptake and transbarrier transport of L-CsA and 
Ptx-NP 
After the dose-controllable aerosolized delivery of the nanodrugs was ensured, 
we performed dose-controlled particokinetics studies with an in vitro cell-model 
of the air-blood barrier consisting of alveolar type II-like A549-Luc(IL-8) cells, 
which are expected to behave identically to the more widely used regular A549 
cells (without luciferase reporter) [184]. Here, we started with L-CsA. L-CsA is 
one of the very few substances, which are suitable for the establishment of vali-
dated in vitro physiologically-based in silico pharmacokinetics models for in-
haled nanodrugs, since two clinical PK studies for L-CsA have been reported in 
the literature, one of them with actual measurement of the pulmonary L-CsA 
dose and one of them starting as early as 15 min after inhalation with monitor-
ing the CsA blood levels ([17, 166]).  
The physiological relevance of an alveolar type II cell barrier is questionable 
since most of the human alveolar surface is covered by alveolar type I cells 
(92.9%) [31]. Recent advances towards providing a readily available alveolar 
type I cell model include the HAELVi cell line (InSCREENeX GmbH, Germany). 
This is an immortalized primary lung epithelial cell line, which represents some 
of the main characteristics of alveolar type I cells, namely the formation of tight 
junctions associated with high trans-epithelial electrical resistance 
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(> 1000 Ω*cm²), low permeability of hydrophilic markers, the presence of caveo-
lae, expression of caveolin-1, and absence of surfactant protein C [70]. While 
these characteristics are highly relevant for in vitro transport studies, this cell 
line was not available when we needed to decide on the most suitable cell type 
for this study. The recently introduced EpiAlveolar cell model (Matek, USA) was 
also not commercially available a few years ago, and is not established for in 
vitro transport studies [82]. Hence, for lack of an established more physiologic 
cell culture model of the alveolar air-blood barrier, A549-Luc(IL-8) cells were 
used here.  
The L-CsA particokinetics study showed an almost constant lung-to-blood 
transport rate of kLB = 1.42/h, which only decreased sharply at 4 h, reaching 
zero at 8 hours after the end of aerosol exposure. At first sight, kLB appears to 
be substantially (2.6-fold) higher than the 0.55/h reported by Schmid et al. 
(2017)[68] for the very same cell model and type of aerosol exposure chamber, 
albeit with a somewhat different L-CsA formulation (calculated from Table 2: kLB 
= 0.0022/(min*cm2)*60 min/h*4.2 cm2 = 0.55/h). If the bias due to partial retain-
ment of L-CsA by the membrane of the Transwell® insert is accounted for (only 
68.5% L-CsA can pass through the Transwell® insert without cells, figure 5.2B), 
the transport rate increases to 0.80/h (0.55/h/0.685), which is 1.8-fold smaller 
than the value reported here (1.42/h). Albeit this difference is still not negligible, 
it is probably justifiable by variabilities in cell characteristics (e.g., barrier tight-
ness) and differences in L-CsA formulation. This also demonstrates that for in 
vitro transbarrier transport measurements with nanodrugs, artefacts due to the 
membrane of the Transwell® insert should be accounted for by including a 
membrane-only control (insert without cell).  
Since the transbarrier transport of L-CsA by A549 cells was measured by HPLC 
analysis of the CsA concentration in the basal compartment (and in the other 
compartments of the Transwell® insert cell model), it was first unclear whether 
the CsA molecules are transported across the cell barrier as part of the intact 
liposomal carrier or as free molecular drug released from the carrier. To gain 
more insights into this issue, fluorescently labeled liposomes (FRET liposomes) 
were manufactured according to Li et al. (2018)[160] and used to clarify cellular 
uptake and transport after nebulization. The ability to discriminate between in-
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tact and dissolved FRET liposomes was demonstrated by the reduction of initial 
total FRET fluorescence intensity to < 7% after Triton-X100 digestion of the lip-
osomes. The relatively larger remainder of < 20% as seen from the biokinetics 
experiments combined with the absence of intact liposomes using DLS analysis 
indicates that an effective detergent such as Triton-X can destroy all of the lipo-
somes, but it cannot dissolve all fragments of the lipid bilayer of the liposomes, 
still leaving some of the two FRET dyes in close proximity yielding a detectable 
FRET fluorescence signal. Hence, it is conceivable that any of the transbarrier 
transport across a cell barrier does also not completely eliminate the FRET sig-
nal [160]. This could explain the rapidly reached (1 h), constant FRET signal of 
ca. 20% in the basal medium in spite of the absence of intact liposomes in the 
basal medium (DLS measurements). 
As prerequisite for using aerosolized delivery of FRET liposomes, it is important 
to note that nebulization of liposomes did not deteriorate the structural integrity 
of the FRET liposomes. This can be concluded from the fact that nebulization 
did not result in appearance of a sub-liposomal size fraction in the DLS size dis-
tribution. This is consistent with previous studies reporting morphological de-
formations after nebulization with a vibrating mesh nebulizer (somewhat elon-
gated rather than perfect spherical liposomes), but no complete loss of structur-
al integrity of the liposomes [68]. 
Our mechanistic cellular uptake study with mechanism-specific inhibitors re-
vealed that caveolae-mediated endocytosis was found to be involved in active 
uptake of FRET liposomes by A549 cells, but not clathrin-mediated endocytosis 
and pinocytosis. Endocytosis is a well-known pathway of cellular nanoparticle 
uptake [185, 186]. It is also well known that the relevance of different endocytic 
uptake can depend on particle size [62]. This size-dependence of uptake mech-
anism was also observed for liposome uptake by Caco-2 cells by Andar et al. 
(2014), where caveolae-mediated endocytosis was involved in the uptake of 
40.6 and 72.3 nm liposomes, while clathrin-mediated endocytosis governed the 
uptake of 97.8 and 162.1 nm liposomes [187]. It is evident from our study, that 
for A549 cells the caveolae-mediated size region is shifted to larger sizes 
(130 nm). 
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In addition to active cellular uptake, also passive drug transport due to fusion of 
the lipid bilayer of liposomes with the cell membranes was reported in HeLa 
cells (human cervix epithelial cells) [188]. As this passive fusion process does 
not require cellular activity, it is likely to be fast and independent of cell type. 
While it is unclear, if membrane fusion leads to separation of the two FRET 
dyes (Dil and DiD) and to a subsequently reduced FRET fluorescence signal, it 
is likely that membrane fusion is not affected by the presence of uptake inhibi-
tors, since these inhibitors are not a detergent and will therefore not destroy the 
lipid bilayer of the liposomes. In any case, fusion may introduce some residual 
FRET signal in the basal medium [160], but this will be independent of the pres-
ence or absence of any uptake inhibitor and will therefore not interfere with the 
effect of uptake inhibitors on FRET-based cellular uptake.  
The kinetics of transbarrier transport of liposomes with hydrophobic loading 
(e.g., Dil-DiD FRET dyes or CsA stored within lipid bilayer of liposomes) with 
and without inhibition of caveolae-mediated endocytic uptake (Filipin) strongly 
suggests that both a fast-passive and a slower-active transport process are in-
volved in transbarrier transport of hydrophobic drugs carried by liposomes.  For 
both CsA and FRET liposomes at 0.1 h after the aerosol delivery, ca. 50% of 
the cell-delivered dye/drug has left the apical compartment independent of the 
presence of uptake inhibitors, while 80 - 95% of the delivered drug has reached 
the basal compartment at 2 h (independent of endocytic uptake inhibition). Only 
at 0.8 h, there was a statistically significant reduced transbarrier transport under 
the influence of inhibition of endocytosis (for FRET liposomes; no data for CsA). 
Thus, endocytic uptake cannot explain the fast initial transbarrier transport, but 
affects the transport kinetics at ca. 1 h. For later time points (2 h), the activity of 
the inhibitor has ceased so that there was not statistically significant difference 
in transport kinetics w/o inhibitor at 2 h (5 - 20% remains in the apical compart-
ment for FRET dyes and CsA).  
Taken together, this suggests that for liposomes loaded with a hydrophobic 
drug (here: CsA or Dil-DiD FRET dye), which is integrated into the liposomal 
bilayer, the following mechanistic and kinetic conclusions can be drawn: 
i) Paracellular transport does not play a significant role in transbarrier 
drug transport, since no intact or fractions of liposomes were found in 
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the basal compartment (DLS measurements). This implies that all of 
the CsA in the basal medium is available in its molecular form (not 
liposomal form). 
ii) Between 40% and 60% of the delivered drug is rapidly transported (< 
0.1 h) across the A549 cell barrier likely due to a passive transport 
process such as liposomes-cell membrane fusion [188] 
iii) Active cellular uptake due to caveolae-mediated endocytosis is slow-
er (ca. 0.8 h – 2 h) and experienced by 30 to 45% of delivered drug  
iv) 5% - 20% of the drug remains in the apical/cell compartment for at 
least 24 h.  
v) The apical-basal (lung-blood) transport coefficient is constant within 
experimental uncertainties during the entire significant transport peri-
od (< 2 h) at kLB = 1.42/h. 
It is important to note that similar in vitro particokinetics results have been found 
for both slow- and fast-release co-polymeric NPs loaded with (hydrophobic) 
Paclitaxel (Ptx-NP). Using A549-Luc(IL-8) cells as barrier model, we found: 
i) Paracellular transport does not play a significant role in transbarrier 
transport of Ptx-NP 
ii) Between 14% (fast-releasing Ptx-NPF) and 26% (slow-releasing Ptx-
NPS) of the delivered drug is rapidly transported (< 0.2 h) across the 
A549 cell barrier, likely due to a passive transport process [188] 
iii) Active cellular uptake due to caveolae-mediated endocytosis is slow-
er (ca. 0.3 h – 0.8 h) and experienced by 40% to 50% of delivered 
drug (slow-releasing Ptx-NPS) 
iv) 33% (fast-releasing Ptx-NPF) - 70% (slow-releasing Ptx-NPS) of the 
drug remains in the apical/cell compartment for at least 24 h.  
v) The apical-basal (lung-blood) transport coefficient is decreasing by 
45% for the fast-releasing Ptx-NPF formulation during the entire peri-
od of significant apical-basal transport (< 2 h). For the slow-releasing 
formulation, a decrease by 80% was observed 2 h after the nebuliza-
tion. This indicates that the storage of Ptx in the lung compartment is 
superior to the lung-blood transport for both formulations. 
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This degree of similarity between the two types of nanodrugs investigated here 
is particularly interesting if we consider that liposomes (lipid vesicle) and copol-
ymeric NPs are fundamentally different in terms of material type and rigidity 
(liposomes: soft; NP: hard), but very similar with respect to size range (L-CsA: 
40 – 100 nm; Ptx-NP: 140 – 200 nm). Thus, size is possible more relevant 
characteristics than material and rigidity for cellular uptake and transbarrier 
transport of (hydrophobic) drugs. We add as a caveat that the situation may be 
different for hydrophilic drugs, since – at least for liposomes - hydrophilic drugs 
are stored within the vesicle and not in the lipid bilayer as for hydrophobic drugs 
[189].   
Based on the in vitro results, the following conclusions can be drawn for the fate 
of liposomes after inhalation in vivo. First, it is likely that passive L-CsA 
transport will determine the lung-to-blood transport after inhalation at a similar 
rate and possibly at an even larger relative magnitude (> 50%), since passive 
transport processes may be quite similar independent of the complexity of the 
barrier. On the other hand, active endocytic uptake and transbarrier transport 
may be somewhat slower in humans due to the more complex air-blood barrier 
in the lung. This issue will be investigated below when comparing transport 
across an epithelial monoculture as compared to an epithelial-endothelial cocul-
ture model. Secondly, CsA (and Ptx) in the blood will be available in its molecu-
lar form (not encapsulated in liposomes) as DLS measurements confirmed the 
absence of intact nanocarriers in the basal medium.  
A few other aspects, which are likely to affect transbarrier drug transport, should 
be considered and explored for relevance in the future. Lung surfactant has 
been shown to increase cell-association of nanodrugs [79]. Also, the effect of 
primary cell culture models such as immortalized alveolar type I cells (hAELVI 
[70]) as well as the transport of these nanodrugs across published breathing-
induced cyclic stretch models ([190]) should be explored.  
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 Advanced cell culture models and their effect on 
particokinetics 
We further aimed to study L-CsA and Ptx-NP particokinetics in scenarios, which 
are more realistic in vivo. 
One strategy, which was applied in the present work, was the investigation of L-
CsA transport under inflammatory conditions. It has been observed that, in vivo, 
inflammatory processes lead to enhanced epithelial permeability due to disrupt-
ed tight junctions [119]. To transfer this observation to the in vitro model in the 
present study, TNF-α was added into the basal compartment of Transwell® in-
sert cultured A549-Luc(IL-8) cells 24 h before the exposure to L-CsA. Dextran 
blue assay 24 h after TNF-α incubation revealed that epithelial permeability was 
increased by a factor of 4 for a TNF-α dose of 16.1 ng/cm², indicating increased 
possibility for paracellular transport of L-CsA. However, L-CsA transport analy-
sis revealed constant CsA doses in the apical/cell compartment over the entire 
monitoring period. Together with the DLS results (no intact particles in the basal 
compartment), this further confirmed that paracellular transport does not play a 
significant role in transport of nanodrugs. From a clinical point of view, this 
demonstrates a significant advantage for the use of liposomal nanocarriers in 
the treatment of lung diseases such as bronchiolitis obliterans (BOS). The in-
corporation of CsA into liposomes can based on the in vitro results, prevent a 
fast clearance through the paracellular route and finally lead to an improved 
lung retained dose in inflammatory conditions. Further, the in vitro results are 
consistent with two reported in vivo studies. Patel et al. (2016)[191] administered 
lipid nanocarriers with an incorporated radioactive label to LPS-treated mice 
and the respective saline control group. Assessment of the radioactive label in 
all organs revealed that there was no faster clearance of the lipid nanocarriers 
under inflamed conditions [191], indicating that the lung-retained dose of the 
nanocarriers remained constant in inflammatory conditions. Arppe et al. 
(1998)[46] found equal CsA levels in healthy and inflamed lungs after the admin-
istration of CsA-liposomes to mice. Consequently, the lung clearance of CsA 
incorporated into liposomal nanocarriers was not enhanced under inflammatory 
conditions [46]. On the other hand, severe outcomes may have to be expected 
for hydrophilic drugs as the translocation of the hydrophilic paracellular tracer 
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dye dextran blue increased by a factor of 4 for 16.1 ng/cm² TNF-α. One exam-
ple for a drug, which is transported by the paracellular transport route, is To-
bramycin [192]. In vivo, Omri et al. (1994)[193] investigated the lung retention of 
Tobramycin after administration to rats (healthy vs. infected (bacterial infection) 
lungs). They found that the Tobramycin concentration in the infected (bacterial 
infection) lungs was below the detection limit already 0.25 h after application. In 
the healthy control group, Tobramycin was detectable 2 h after the application. 
More importantly, the administration of Tobramycin as a liposomal formulation 
allowed the detection in both groups even after 16 h [193]. This confirms that 
liposomal drug formulations prevent a fast depletion of the lung retained dose 
by the paracellular route. 
Another strategy, which was applied to increase the relevance of the in vitro 
model of A549-Luc(IL-8) cells, was the addition of EA.hy926 endothelial cells on 
the basal side of the Transwell® insert for the Ptx-NP studies. This did not in-
crease the barrier resistance against particle transport, as the Ptx dose in the 
basal compartment after Ptx-NP exposure was either comparable to the mono-
culture of A549-Luc(IL-8) cells (fast-releasing Ptx-NPF) or even increased 
(slow-releasing Ptx-NP). Moreover, TEER values and dextran blue translocation 
between the mono- and the coculture were comparable, which is in line with 
previously reported results [78, 83]. One initial hypothesis for the accelerated 
transport of Ptx-NP by the coculture model was that EA.hy926 led to opened 
tight junctions of A549 cells, e.g. via cross-talk [194]. However, it has been ob-
served that Ptx is hardly transported by the paracellular route of epithelial cells 
[195]. Another hypothesis was additional transport by either the endothelial 
paracellular or the endothelial transcellular route. Both transport pathways for 
Ptx are described for endothelial cells [196, 197]. Thus, it can be hypothesized 
that both (para- and transcellular) pathways accelerated Ptx transport after ad-
dition of endothelial EA.h926 cells to the in vitro model. Consequently, our re-
sults confirm that the addition of EA.yh926 cells lead to accelerated transport of 
nanodrugs (slow- and fast-releasing Ptx-NP) and dextran blue. However, the 
impact of increased paracellular permeability of coculture models in vivo has not 
been clarified yet [198].  
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As Ptx-NP are in preclinical development for the treatment of pulmonary arterial 
hypertension (PAH), another strategy to enhance the clinical relevance of the 
co-culture model was the investigation of Ptx-NP transport by a diseased in vitro 
PAH model. One of the characteristics in the development of PAH is an im-
paired lung endothelium, which is among others initiated by inflammatory condi-
tions [178, 199-201]. TNF-α was found to play a prominent role as it promotes a 
PAH phenotype [202] and is, in addition, considered as a target for the treat-
ment of PAH [203]. To establish an in vitro PAH disease model, EA.hy926 cells 
were challenged with TNF-α for 24 h prior to establishment of a coculture with 
A549-Luc(IL-8) cells. This demonstrated a higher permeability, which led to an 
increase of the paracellular transport marker dye dextran blue. In comparison to 
the approach by Hermanns et al. (2004), who added TNF-α into the basal com-
partment leading to activation of both cell lines in an epithelial-endothelial co-
culture model representing the pulmonary air-blood barrier [204], the enhanced 
permeability could directly be attributed to endothelial cells in the present work. 
The diseased coculture model was then exposed to Ptx-NP. Although the para-
cellular permeability was increased due to challenged EA.hy926 cells, the 
transbarrier transport of Ptx-NP, which were aerosolized on the epithelial cells 
on the apical side, was non-significantly changed and the cellular association of 
Ptx remained constant. This suggests that the interaction of aerosolized Ptx-NP 
with the epithelium outweighed the transport of Ptx by challenged endothelial 
cells. Further, it promises a significant advantage for the use of co-polymeric 
nanocarriers in the treatment of PAH, as the increased endothelial permeability 
did not significantly decrease the cell-association of Ptx. 
All in all, the applied strategies confirm the potential of drug carrier systems in 
the therapy of lung diseases associated with inflammatory conditions as a fast 
clearance via the paracellular route is avoided. 
 Evaluation of the in vitro physiologically-based in silico 
pharmacokinetics 
Another goal of this thesis was to increase the clinical relevance of the L-CsA 
and Ptx-NP particokinetics studies by predicting the pharmacokinetics (PK) in 
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human based on the obtained A549-Luc(IL-8) cellular nanodrug transport rates. 
Here, we applied the concept introduced by Bachler et al. (2015), who assessed 
A549 cellular transport rates of gold nanoparticles (in vitro) and combined the 
rates with PBPK modeling (in silico) to predict organ doses for the same set of 
gold nanoparticles in mice (in vivo) [52]. However, we focused on one com-
partment only (blood) and predicted the dose as a function of time to ultimately 
obtain the pharmacokinetics. All in all, three steps were introduced to translate 
the L-CsA particokinetics into pharmacokinetics. 
First, the lung deposited L-CsA dose for the clinical PK study has to be ob-
tained. In general, this can either be accomplished by using computational aer-
osol-lung deposition models (e.g. MPPD model, Miller et al. (2016)[205]), by es-
timating this from known average aerosol deposition fractions for the specific 
nebulizer used (here: eFlow® nebulizer, Pari Pharma GmbH, Germany; ca. 20 – 
40% of the invested dose), or by using dosimetry data from a comparative 
study. The latter is the case here since in the L-CsA inhalation study, which is 
reported by Behr et al. (2009) [17], the peripheral lung deposition of CsA was 
determined from radiometric measurements as 22% of the nominal dose. 
Secondly, the dose, which is transferred from the lung into the blood, has to be 
obtained. Here, we used the results from the L-CsA particokinetics studies to 
express the transported dose as the parameter kLB. Interestingly, also cell-free 
models have recently been introduced to represent the air-blood barrier in vitro 
and to simulate lung-blood transport. One example is the DissolvIt technology, 
which uses a polycarbonate membrane to resemble the in vivo air-blood barrier 
in vitro [206]. It was shown that the absorption of inhalable drugs by the mem-
brane could successfully be transferred into pharmacokinetics in patients by 
PBPK modeling [207]. However, our goal for this study was to clarify the fate of 
nanodrugs after cellular transport and to enhance the in vivo relevance of 
Transwell® insert models – hence, we used the insert model. 
Thirdly, the depletion rate of CsA in the blood as a result of metabolic CsA deg-
radation and/or excretion has to be obtained. In general, one can use reference 
clinical studies to describe the elimination and excretion of the drug from the 
blood ([52, 61, 208, 209]) or one can use software such as PK-Sim ([208, 210]), 
which summarize parameters that contribute to elimination and excretion of 
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commonly used drugs in the blood. In the present work, a published[166] L-CsA 
PK profile was utilized to describe the depletion of CsA in the blood and finally 
expressed as the in silico input parameter kloss.  
The combination of the three steps showed that the modeled and published PK 
data agreed within experimental and modeling uncertainties, and showed that 
the combination of in vitro and in silico approaches demonstrates excellent po-
tential to deliver in vivo relevant results.  
The concept was also applied to predict the Ptx PK in human after inhalation of 
slow- and fast-releasing Ptx-NP. In comparison to the CsA PK, Ptx cmax levels 
were 2.8-fold (fast-releasing) and 5.1-fold (slow-releasing), respectively, re-
duced for a comparable lung deposition fraction since max. kLB values for both 
Ptx-NP formulations (Ptx-NPF: kLB,max = 0.56/h, Ptx-NP: kLB,max = 0.30/h) were 
significantly lower than for L-CsA (1.42/h).  
From the predicted PK profiles, the following conclusions can be drawn: 
i) The nominal dose is a linear determinant of the maximum serum level 
(as seen for the Ptx-NP model) 
ii) The model promises low systemic Ptx levels after inhalation of Ptx-
NP. As comparison: Intravenous application of 10 mg Ptx would lead 
to 10-fold increased cmax levels of ca. 250 ng/mL (reference studies: 
[211] or [179]) 
iii) Lung-to-blood transport of aerosolized nanodrugs is the main factor, 
which leads to a reduction of the lung-associated drug dose after in-
halation. The model did not consider clearance of nanodrugs by alve-
olar macrophages, which are typically involved in clearance and me-
tabolism of inhaled nanoparticles [21]. It can thus be concluded that 
macrophages do not interfere in the lung-blood transport of liposomal 
and polymeric drug formulations. This can be explained by the fact 
that phagocytosis by alveolar macrophages typically occurs for sizes 
> 1 µm [212], and the nanodrugs were below this threshold. 
iv) Transwell®-insert cultured epithelial cells are an efficient model to 
predict the pharmacokinetics of aerosolized drugs. For Ptx-NP, kLB 
values for a more physiological model (A549-Luc(IL-8) epithelial cells 
and EA.hy926 endothelial cells) were available. However, L-CsA 
6 Discussion  113 
 
modeling showed that A549-Luc(IL-8) cellular transport rates are suf-
ficient enough to show a match to clinical L-CsA data. Hence, we 
used epithelial rates for the modeling of the Ptx pharmacokinetics.  
 
All in all, A549-Luc(IL-8) cells were successfully used as in vitro model for the 
pulmonary air-blood barrier. This allowed the calculation of the CsA and Ptx 
pharmacokinetics, which was successfully validated for CsA by comparison with 
published clinical profiles. 
 Comparison of clinical pharmacokinetic parameters for various 
drugs 
The role of the nominal dose as linear determinant of cmax levels was confirmed 
by analyzing maximums serum levels of published inhalation studies. The com-
parison of cmax levels of various drug formulations (L-CsA, liposomal Amikacin, 
mixture of free and liposomal Ciprofloxacin, Levofloxacin, and Tobramycin) after 
inhalation as a function of the nominal dose showed a correlation of 92%. This 
is surprising as the correlation includes drugs with and without drug carrier sys-
tems, patients with different diseases (cystic fibrosis, bronchiolitis obliterans, 
and non-cystic fibrosis bronchiectasis), and different types of nebulizers. How-
ever, it is important to mention that the antibiotic Levofloxacin was excluded 
from the correlation as it showed a more than 2-fold higher cmax level as com-
pared to the fit. This can be a consequence of high variabilities in lung deposi-
tion, which directly influence cmax levels [213]. Especially for inhalable antibiotics 
used for the therapy of cystic fibrosis, high “between-subject variabilities” [214] 
are common, i.e., 50% - even 100% of the mean cmax value [169]. Taking this 
variability into account, it can be assumed that the 2-fold increased cmax level of 
Levofloxacin is non-significant compared to the correlation of the other investi-
gated drugs.  
Focusing on L-CsA, the correlation suggests that CsA molecules are released 
once the liposomes reach the epithelial barrier as the slope of the linear curve 
describing cmax after inhalation of CsA and L-CsA (cmax = 1.7 * 10-6 mL-1 * nomi-
nal dose), respectively, was similar to the one derived from all of the drugs (cmax 
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= (2.7 ± 1.1) (2 SD) * 10-6 mL-1 *nominal dose). This hypothesis is supported by 
our in vitro L-CsA transbarrier studies. They showed the absence of intact lipo-
somes in the basal compartment and confirmed an initially high transport of CsA 
into the basal medium (blood). On the other hand, the liposomal nanocarriers 
majorly remained cell-associated. Consequently, an initial burst of the lipo-
somes occurred, typical for aerosolized nanocarriers [215]. Transferring this 
result to the in vivo side, it can be suggested that liposomes majorly burst after 
lung deposition, leading to high drug dose, which is transported into the blood 
circulation in a similar way as the inhalation of the free drug counterpart.  
However, the ultimate goal of inhalation therapy is to target the lung – but there 
are challenges to characterize the fate of liposomes in vivo after inhalation. Cur-
rently, two methods are majorly used to evaluate the lung deposition of inhaled 
drugs in human. One of them is to estimate the lung deposition of inhaled drugs 
indirectly via comparing the PK of the drug in the blood [213]. However, the ini-
tial burst of drugs entrapped in nanocarriers and the comparable cmax values, as 
observed in correlation to the nominal dose, make it challenging to highlight the 
advantages of nanocarrier systems. In other words, prolonged interactions at 
the lung side do not necessarily result in reduced systemic drug levels [216]. 
However, cmax can be used to evaluate effective lung deposition, according to 
Strong et al. (2018)[216]. If this value is achieved within 5 – 30 min, it can be 
concluded that the drug was sufficiently distributed in the lungs [216]. The other 
method to estimate the lung deposition is γ-scintigraphy [213], which images 
lung deposition of nanocarriers modified by radioactive labels [51] [17]. For lipo-
somes, however, this method demonstrates the disadvantage that the fate of 
the liposomal shell can be tracked, but not the fate of the active incorporated 
drug. Scintigraphy, however, can be applied to image the distribution pattern of 
inhaled drugs [217]. 
The FRET technology shows the potential to give more insights into the fate of 
nanocarriers in the lung tissue as it can track the direct interactions with liposo-
mal shells [174]. This also might give an enhanced view, which barrier in the 
lung opens the liposomes and where exactly the drug is released. 
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 Evaluation of Ptx-NP as a therapeutic option for pulmonary 
hypertension (PAH) 
Besides the pharmacokinetics, we also aimed to evaluate the efficacy of Ptx-NP 
with the physiological cell model of the pulmonary air-blood barrier consisting of 
A549-Luc(IL-8) and EA.hy926 cells as Ptx-NP are currently in the preclinical 
development for the therapy of PAH. Two significant findings in the present 
work confirmed the potential of the model to test the efficacy of aerosolized 
drugs for PAH treatment. 
First, the addition of endothelial EA.hy926 cells significantly increased the intra-
cellular Ptx levels (figure 5.25) in comparison to the control setup, where only 
A549-Luc(IL-8) cells were exposed to Ptx-NP. As endothelial cells are target 
cells of pulmonary hypertension [200], cellular Ptx association is in favor.  
Secondly, genes, which are downregulated in PAH [19], were upregulated in 
EA.hy926 cells after Ptx-NP exposure of the in vitro model, most importantly 
FOXO1 and FOXO3. Moreover, SOD2 was upregulated in endothelial cells after 
Ptx-NP exposure, which is in favor of the observations made with SOD2 in 
PAH. Single nucleotide polymorphism analysis of SOD2 in a study carried out 
by Xu et al. (2017) showed that reduction of SOD expression, which is linked to 
increased oxidative stress, was associated with the development of pulmonary 
hypertension [218]. In addition, SOD2-deficient myeloid cells were shown to 
promote the hyper-proliferative PAH phenotype of human arterial smooth mus-
cle cells [219]. Likewise, the activation of GADD45 confirmed the therapeutic 
potential of Ptx-NP. The DNA-damage inducible GADD45B gene was found to 
be decreased in primary arterial endothelial cells isolated from pulmonary hy-
pertension patients [220]. Furthermore, phosphorylation of the GADD45 protein 
was decreased in primary arterial smooth muscle cells isolated from PAH pa-
tients [221].  
All in all, the results showed that the air-blood barrier in vitro model (A549-
Luc(IL-8) cells as epithelium and EA.hy926 cells as endothelium) could be used 
to study the efficacy of Ptx-NP in the field of PAH. In terms of simplicity, this 
model is advantageous compared to approaches that rely on the use of primary 
human material [19]. 
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 Estimation of toxicity onset in rats based on in vitro data 
Although Ptx-NP showed efficacy in terms of gene upregulation and cellular 
storage, toxicity was found, i.e., cell viability was reduced to about 50% for 
6.4 µg Ptx/cm² (both formulations) and for 3.8 µg Ptx/cm2 (slow-releasing only). 
The experiments with placebo Ptx-NP (fast-releasing) indicated that this could 
be attributed to the nanoparticles, not to the Ptx loading. As the next step in fol-
lowing preclinical studies would be the application of Ptx-NP to rats by inhala-
tion or instillation, an estimation of the toxicity onset in rats based on in vitro 
data will be given. Moreover, this approach will also allow estimating the thera-
peutic window.  
As mentioned, a decrease in metabolic activity was found for a dose of 6.4 µg 
Ptx/cm² or 118 µg Ptx-NP/cm², respectively. Ding et al. (2020) reported that a 
dose of 0.86 cm²/cm² zinc oxide (ZnO) (surface area/cell growth area) led to a 
decrease in the cell viability by 50% [93]. Schmid et al. (2016) reported an onset 
of inflammatory processes in rats after ZnO instillation for a dose of 15 cm²/g 
[222]. 1 g of a rat lung typically refers to a surface area of 3000 cm², taking into 
account a rat lung surface area of 4000 cm² and a lung weight of 1.3 g [167]. 
Therefore, 15 cm²/g refers to a ZnO dose per lung surface area of 
0.005 cm²/cm². Thus, the onset of toxicity after ZnO exposure in vitro is 
achieved by a 172-fold increased dose as compared to in vivo. Based on these 
observations, an in vitro-in vivo-extrapolation (IVIVE) factor of 100 – 1000 can 
be estimated. With this IVIVE factor, a rat bodyweight of 300 g ([167]), and a rat 
lung surface area of 4000 cm² ([167]), an onset of adverse (inflammatory) ef-
fects may have to be expected for a dose of 1.6 – 16 mg/kg if Ptx-NP are ad-
ministered via instillation into rats (e.g. by micro sprayer application). 
This approach can also be applied to estimate the therapeutic window. The in 
vitro gene regulation profile of Ptx-NP was similar to that observed by a mouse 
model of idiopathic pulmonary arterial hypertension (IPAH) [19]. FoxO1 up-
regulation in EA.hy926 cells was found for a nominal dose of 1 – 3 µg/cm². On-
set of therapeutic efficacy in rat PAH models can hence be expected for 0.34 – 
3.4 mg/kg if Ptx-NP are administered via instillation. However, the in vitro data 
suggest that the therapeutic window of Ptx-NP may appear to be relatively nar-
row (1 – 3 µg/cm2). This would have to be further substantiated by exploring the 
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onset dose for therapeutic efficacy in the following steps. Nevertheless, the ap-
plied approach has the potential to find starting doses for following preclinical 
studies with a focus on toxicity and onset of efficacy. 
 Comparison of polymeric and liposomal nanocarriers 
As described, the two types of nanodrugs (L-CsA, Ptx-NP) showed a high de-
gree of similarity with regard to particokinetics. However, some differences were 
obtained, which are summarized in table 6.1 and discussed below. 
 
Table 6.1: Comparison of liposomal and polymeric nanocarriers 
 Liposomal nanocarrier Polymeric nanocarrier 
Viability No observation of toxicity[68]* Observation of toxicity* 
Adverse effects on the 
barrier integrity of the 
cells 
No No  
Transport at ALI con-
ditions 
Burst-like Burst-like 
PDI after nebulization Monodisperse 0.283 Monodisperse 0.100  
Volume-based particle 
diameter 




30% (Ptx-NP slow) 
65% (Ptx-NP fast) 
Release in basal me-








Release of molecular 
drug required? 
Yes Yes 
* With 15.1% (w/v), the L-CsA stock solution was even 3.8-fold higher concentrated as the Ptx-
NP stock solution and consequently led to higher cell-delivered doses 
 
While toxic effects were observed for polymeric nanocarrier, adverse effects of 
L-CsA on cellular viability were not reported by Schmid et al. (2017) [68].   
6 Discussion  118 
 
Liposomes were characterized by smaller particle size as compared to the pol-
ymeric particles. Although nanocarriers show great advantages such as pro-
longed effects [15], the demonstration of non-toxic effects is the more important 
step in the development [223]. As shown, this can be evaluated by simple in 
vitro models of the air-blood barrier.  
The transport profile obtained by A549-Luc(IL-8) cells demonstrated burst-like 
transport for both of the particles. Nevertheless, the asymptotic value (transport 
after 24 h) for the polymeric particles was below the value for the liposomes, 
indicating accelerated transport for liposomes. 
Caveolae-mediated endocytosis was involved in the uptake of both nanocarri-
ers. Interestingly, paracellular transport played a role for the drug loading of pol-
ymeric particles when the A549-Luc(IL-8) cell setup was extended to a cocul-
ture model with the endothelial cell line EA.hy926. 
The Ptx-NP remained stable during the aerosolization process. In contrast to 
this, a slight degradation of liposomes was measured by an increase of the pol-
ydispersity index (PDI) (data not shown), which is a direct measure for the dis-
tribution of the particles [175]. However, the PDI after the nebulization was still 
in an acceptable range (< 0.3 [176]) for aerosolized delivery of liposomal drug 
formulations.  
In summary, the transport profiles for both drug carrier systems showed re-
markable similarities.  
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 Limitations 
Given limitations of this study include 
 
a) Clarifying the contributions of each cell line on the transbarrier transport 
of the nanodrugs 
b) In vivo validation of the observed higher paracellular transport kinetics for 
the epithelial-endothelial coculture 
c) Limited tight junction expression by A549 cells 
d) PK can be modeled with literature data but not predicted because of a 
missing loss compartment 
 
These could be extended by 
 
a) Aerosolization of the free drugs (CsA and Ptx) – however, this is chal-
lenging due to the limited drug solubility and the fact that they could bind 
to media ingredients, especially fetal calf serum, more preferentially.  
b) PK studies in animal experiments. This thesis used epithelial transport 
rates to match the PK of a slow and a fast-releasing Ptx-NP formulation. 
If there are comparable cmax values after the application to animals, the 
enhanced paracellular permeability of the coculture has in vivo impact 
c) Use of alternative cell lines. However, the nanodrugs were not transport-
ed by the paracellular transport pathway of A549 cells, but showed 
strong cell-association. Thus, A549 cells are a suitable cell line to match 
in vitro and in vivo PK. The successful use of A549 cells to predict rele-
vant in vivo parameters has also been reported by Bachler et al. (2015) 
[52] 
d) Use of microfluidic devices to simulate drug clearance in vitro, as de-
scribed by Frost et al. (2020) [224] 
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7 Conclusions 
Aerosolized delivery of nanodrugs to ALI cultured in vitro cell models of the al-
veolar air-blood barrier with the VITROCELL® Cloud 6 system revealed that 
• Cellular transport studies on Transwell® inserts of nanocarriers need to 
include a membrane-only control (insert without cells) 
• Cellular uptake of nanodrugs plays a significant role in transbarrier 
transport rates 
• Dose finding with in vitro models of the air-blood barrier allows for esti-
mating the therapeutic window of nanodrugs  
• Cellular models can be used to estimate the onset of toxicity of aeroso-
lized nanodrugs in vivo 
• Cellular models can be used to select superior formulations of nanocarri-
ers 
• Cellular models can be combined with PBPK models to predict the in vi-
vo PK of nanodrugs 
• Cellular models can be used to confirm the potential of prolonged 
nanocarrier interaction on the target site, even in inflammatory conditions 
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8 Outlook 
Dose-controlled, aerosolized delivery of drug-loaded nanocarriers focusing on 
cell-delivered dose at ALI cell culture conditions has the potential for quantita-
tive prediction of therapeutic windows as well as pharmacokinetics and phar-
macodynamics of drugs in animals and humans.  
This can significantly reduce the risk of failure of drugs in both animal toxicology 
studies and clinical studies.  
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 Appendix 
1. Simple discrete modeling 
 
Simple discrete modeling was introduced to match in vitro Cyclosporine A 
transport rates with the clearance of CsA from the plasma after inhalation. Clini-
cal data for L-CsA published by Breath Therapeutics GmbH were used to obtain 
the removal rate of CsA from the blood.  
In detail, the translocation of L-CsA across A549-Luc(IL-8) cells after exposure 
in the VITROCELL® Cloud 6 system was used to calculate the fractional in vitro 
transport rate kLB (A.1-1), i.e. the fraction of the drug transported across the al-
veolar barrier model per time for a given time layer (index i). 
 
 








i:     index for time points at which data was collected, 0 – 24 h  
kLB:     in vitro fractional CsA transport rate, h-1 
tb: in vitro transbarrier transported CsA dose (i.e. dose in the ba-
sal medium), µg 
rc+a:    in vitro CsA dose in cell and apical compartment, µg 
 
The fractional removal of CsA from the blood plasma was calculated from pub-




𝑘𝑙𝑜𝑠𝑠𝑖 =  
𝑐𝑖+1−𝑐𝑖
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kloss:     in vivo fractional CsA loss rate from the blood, h-1 
c:     concentration of CsA in the blood, ng/mL 
t:      time, h 
 
With these parameters one can now calculate the time course of the drug dose 
in the lung, where we focus on the dose in the peripheral lung (Li), which is 
most relevant for transport from the lung into the blood. At time point zero (di-
rectly after end of inhalation), L-CsA in the lung is the fraction of the (nominal) 
dose in the inhaler multiplied by the lung-deposited fraction (L0 = fdep Dnominal), 
which was experimentally determined by Behr et al. (2009) [17], was used 
where the peripheral L-CsA deposition was measured as 22% of the nominal 
dose. During each time step (i), the pulmonary dose (Li) can be calculated from 
the initially deposited dose (L0) subtracted by the CsA dose currently present in 
the blood (VBlood*ci), and the sum of all of the CsA dose removed from the blood 
(sum of VBlood(kloss*ci). 
 
 
L:      actual dose of CsA in the lung, µg 
fdep:    peripheral L-CsA deposition fraction 
Dnominal:   L-CsA dose in the inhaler, mg 
 
Similarly, the CsA dose transported from the lung to the blood (mLB) at each 
time step can be calculated from the in vitro lung-blood transport rate (kLB) and 
the lung dose Li (from in vivo data using equation (A.1-3)). 
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Dividing this time series of CsA doses transported from the lung into the blood 
per time interval (∆mLBi/∆t) by the total human blood volume finally resulted in 
the temporal PK profile (CsA serum concentration) of the inhaled drug. Compar-
ison of mLB,i/VBlood with the clinically measured serum concentration allows as-
sessment of the predictive capacity of the in vitro transport rate in terms clinical 
outcome.  
 








 𝑚𝐿𝐵𝑖 = 𝑚𝐿𝐵𝑖−1 + 𝑘𝐿𝐵𝑖 ∙
𝑟(𝑐+𝑎)𝑖+1
𝑟(𝑐+𝑎)0.25ℎ 
∙ 𝐿𝑖 ∙ (𝑡𝑖 − 𝑡𝑖−1) (A.1-4) 
𝑑𝑚𝑏𝑙𝑜𝑜𝑑
𝑑𝑡












= 𝑘𝑙𝑜𝑠𝑠 ∙ 𝑚𝑙𝑜𝑠𝑠 (A.2-4) 




mlung:    dose in lung compartment after inhalation, mg 
mblood:    dose in blood compartment after inhalation, mg 
mloss:    dose in loss compartment after inhalation, mg 
mremainder:   dose in loss compartment after inhalation, mg 
?̇?𝑑𝑒𝑝:     inhaled dose as a function of inhalation time, mg/min 
t:     time, min 
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 Value in vitro/in vivo Aim Reference 
Alveolar surface area 
(cm²) 
143 in vivo 
Initial L-CsA 
dose in the lung 




0.221 in vivo 
Initial L-CsA 
dose in the lung 
Behr et al. 
(2009) 
Nominal L-CsA dose 
(dose in PARI eFlow® 
inhaler) (mg) 
10 in vivo 
Initial L-CsA 
dose in the lung 
Kappeler et 
al. (2019) 





Clinical CsA data (se-
rum) (ng/mL) 





CsA dose in basal medi-
um (µg) 




CsA dose in apical + cell 
compartment (µg) 




Remainder rates (1/h) fit In vivo 
Calculation of 
kBR and kRB 
- 
Inhalation time (min) 9 in vivo 
Calculation of 
mdep 
Behr et al. 
(2009) 
Total human blood vol-
ume (mL) 
5775 In vivo 
Calculation of 
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List of abbreviations 
ALICE   ALI Cell Exposure 
LCI    Live Cell Imaging 
SEM    Scanning Electron Microscope 
QCM    Quartz Crystal Microbalance 
ALI    Air-Liquid Interface 
CsA    Cyclosporine A 
L-CsA    Liposomal Cyclosporine A 
Ptx-NP   Paclitaxel-laden nanoparticles 
Ptx    Paclitaxel 
TNF-α    Tumor Necrosis Factor-alpha 
PDI    Polydispersity Index 
DAPI    4′,6-Diamidin-2-phenylindol 
DLS    Dynamic Light Scattering 
FRET    Fluorescence Resonance Energy Transfer 
FCS    Fetal Calf Serum 
LDH    Lactate Dehydrogenase 
WST-1   Water Soluble Tetrazolium Salt 1 
IL-8    Interleukin 8 
DAPI    4',6-diamidino-2-phenylindole 
BODIPY   Boron-dipyrromethene 
PBS    Phosphate buffered saline 
DMEM/F-12  Dulbecco’s Modified Eagle Medium/Ham’s F-12 Medium 
Luc    Luciferase 
fdep     Deposition factor 
Ainsert    Area of the Transwell® insert, cm² 
kLB     in vitro obtained lung to blood transport rate 
kloss    in vivo loss rate 
kBE     elimination rate of a drug in the blood 
kBR transport of a drug from the blood into the remainder (rest of 
the body)  
kRB reflux of the drug from the blood into the remainder 
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Dtot    Dose of an aerosolized drug per Transwell® inserts 
rm     Dose retained by the membrane 
rc+a Dose of an aerosolized drug retained by the cells plus the 
amount of an aerosolized drug attached to the cells  
tb transmitted dose into the basal compartment when cells are 
present 
tb,0 transmitted dose into the basal compartment for a membrane-
only control 
ISDD    In vitro Sedimentation, Diffusion and Dosimetry model  
SD     Standard Deviation 
SEM    Standard Error of the Mean 
n     number of experiments 
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